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ABSTRACT 
 
Advances at the interface:   
merging information technologies with genomic methodologies 
 
by 
 
Faye Marguerite Walker 
 
 
Deoxyribonucleic acid (DNA) is a molecule whose importance towers like a 
colossus in the sweeping field of biomedicine. The chemical structure of double stranded 
DNA is itself a helical tower that forms not only the backbone of medical research, but of 
life itself. Yet, we cannot let DNA be constrained to this role of solid, rigid building block if 
we wish to utilize its full potential. In its single stranded form, DNA can take on unexpected 
tertiary shapes that allow it to interact with polymerases, proteins, and organic molecules. 
This ability gives nucleic acids immense potential for molecular recognition. From 
monitoring a state of health to identifying toxins in drug development, using DNA as a 
sensing element can bring valuable information.  
Clinical diagnostics have benefited enormously from the sensitivity, specificity, and 
rapidity of nucleic acid testing (NAT). It can be easy to take blood donor screening, 
heritable genotyping of newborns, and other standard operating procedures for granted in the 
developed world. Developing nations with as few as one physician for every 100 people are 
lacking in the healthcare infrastructure (to say the least) to provide these molecular tests. 
  x 
The key to unlocking the progressions made by NAT in identifying causative agents of 
disease comes in the form of a ubiquitous tool:  mobile phones. Almost 7B people in the 
world own cell phones. By combining the optical imaging capabilities and computational 
powers of mobile phones with a streamlined amplification platform, the ability to detect 
diseases becomes available to those who could truly reap its benefits. 
The synergistic nature of merged technologies is something that extends beyond nucleic 
acid amplification tests (NAATs) to analysis of recombinant DNA products. Most fields 
have single-use products that are essential for one purpose but otherwise hidden from view. 
When brought to the attention of other disciplines, nucleic acid analysis tools such as next 
generation sequencing (NGS) can segue from providing information on full genomes to 
identifying highly represented DNA affinity agents from candidate pools. Bringing the 
systems of particle display, high throughput sequencing (HTS), and in situ microarray 
synthesis to a sequence selection process enhances screening capabilities to the extent that 
hundreds of sequences can be identified en masse as binding to thousands of targets. 
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Chapter I 
Introduction 
Since its inception by Francis Crick and James Watson in 1953[1], the three-dimensional 
model of DNA has remained largely unchanged. The story behind physicist Crick and 
biologist Watson’s landmark discovery is one of applying insider knowledge to an outside 
field. Crick could explain x-ray diffraction techniques; Watson could predict the orientation 
of the sugar-phosphate backbone; together, they laid the groundwork for genetics, genomics, 
and DNA-based studies that are dominating twenty-first century medicine. The message 
encoded in genomic DNA molecules can explain, on a chemical level, the form and function 
of human disease. Today, a burgeoning movement in biomedicine has laid the foundation 
for personalized, preventative, and predictive initiatives[2–4]. Scientific advancements in 
turning personal devices into monitoring systems are enabling this trend towards rapid, 
customized diagnostics. The nature of handheld phones and downloadable software makes 
them an obvious choice in applications for mobile healthcare (mHealth) platforms. 
Alongside current efforts to adapt bioanalytics for field usage, powerful methods for 
diagnosing genetic and infectious disease from nucleic acids targets are making pathogen 
identification and assessment possible on a timeline of minutes or hours. Genomic resources 
are aiding other industries besides diagnostics, including pharmaceuticals. Approval of 
therapeutics by regulatory agents becomes easier when the composition of the drug can be 
understood and decoupled from any possible contaminants. Once more, genome-scale 
analyses have the ability to enhance product assessment in drug manufacturing pipelines. 
We will see in the course of this dissertation that when established industries integrate DNA 
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as a resource in their development of modern assays, the result is a stunning gestalt of 
analytical force. 
 
A.  Thinking small:  base by base 
Just as GoogleEarth breaks down terabytes of digital mapping data to display street-level 
and three-dimensional views of a particular city, genetic technologies give clinicians the 
ability to deconstruct an entire genome of information with single nucleotide resolution. As 
an increasing number of genomes are sequenced, catalogues of genes can be exploited to 
serve as targets for clinically useful diagnostic tests. Perhaps the most salient example of 
NAATs as a powerful clinical tool is their status as the gold standard for detection of 
Chlamydia trachomatis (C. trachomatis) and Neisseria gonorrhoeae (N. gonorrhoeae)[5]. In 
the case of most infectious diseases, culture or serological techniques are the dominant 
choice for examining collected specimens. The limitations of these visualizations are 
markedly apparent:  microscopic identification is hugely reliant on the ability of the 
laboratorian to successfully recognize a pathogen, and culturing methods depend entirely on 
the time-dependent ability of an organism to propagate on artificial media.  
Analysis techniques that operate at the level of the genome have exquisite sensitivity, as 
well as the ability to do away with the slow turnaround of culturing. Systems based on DNA 
hybridization technology made early inroads into microbiology through plasmid profiling 
and bacteriaphage typing[6], but it was the cannonading launch of the polymerase chain 
reaction (PCR) that simplified and accelerated the outdated arsenal that had been the main 
weapons of life scientists[7]. The global market for DNA-based diagnostics is expected to be 
worth $37B by 2018, within which PCR-based amplification tests claim the largest share of 
$16B[8]. For all the advantages of a well-characterized, developed, and established method 
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such as PCR, its need for cyclic heating and cooling steps goes hand-in-hand with costly and 
bulky instrumentation. We sought for a solution to the prohibitive costs that typically 
impede PCR usage in settings with scant or stretched equipment and found it in a ubiquitous 
tool:  the personal desktop computer (PC).  
 
B.  Care for those who will choose, use, and pay the dues 
The link between design and function is as strong in the field of medicine as in the 
market of luxury sports cars. Diagnostic tests and therapeutic treatments are often only 
suitable for laboratory testing in a clinic. From a global point of view, we can see that 
eradicating diseases begins with preventative measures to stop the spread of infection and 
enable treatment—and endemic countries, where resources are often lacking, are where 
rapid, deployable tests are needed most. Our vision of a platform that uses preexisting 
products, such as readily available PCs, gets effective results without the need to 
manufacture or distribute entirely new instruments. 
Telemedicine, mHealth, and remote diagnostics all describe ways of leveraging 
alternative medical technologies to make healthcare more cost-effective and obtainable. A 
recent report on cell phone activities found that 96% of the world’s population (90% being 
the statistic for developing nations) holds a mobile phone subscription[9]. Penetration of 
cellular phones is only likely to increase in the coming decades, as the rapid advances in 
digital technology and the economic forces behind Moore’s Law have lowered the overall 
costs associated with mobile technologies. This steady increase in change is accompanied by 
refinements in the optical, processive, and connective abilities of cell phones and smart 
phones[10]. The best aids to point-of-care (POC) diagnostic work may in fact come in the 
form of a camera phone’s imagers and software-enabled computations. 
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C.  The body electric and problematic   
The complexity of life has the unfortunate consequence of impeding NAT from the 
inside out. In biologically derived matrices, the sequential steps of target isolation, 
amplification, and detection constitute the overall testing process for nucleic acids. Separate 
steps are a necessity due to the presence of nefarious agents that can obstruct the isolation of 
nucleic acids from within target cells, degrade the targets beyond recognition, or block the 
final detection mechanisms from properly measuring the desired molecules[11]. This theme 
carries through from bodily samples—such as urine, saliva, and blood—to other complex 
sample types, such as cell lysate. Rather than attempting to perform the primary step of 
extraction at the POC, numerous research groups have removed this bottleneck by directly 
detecting nucleic acids in crude sample matrices. 
Though it is by no means sui generis, the challenges of diagnosing bloodborne 
pathogens at the POC are greatly in need of developments to identify nucleic acids without 
extensive pretreatment[12,13]. Along with containing DNA or RNA templates that indicate 
diseased states, blood is laden with heme compounds, anticoagulants, and EDTA that inhibit 
DNA polymerase activity[14] or chelate the necessary cofactors[15]. Any alteration that these 
inhibitory reagents make on the amplification performance will hugely skew attempts to 
quantify the amount of target DNA present in a sample. Standard techniques to monitor the 
DNA produced in a reaction are reliant on analyzing a signal in real time. We were driven to 
investigate whether quantitative techniques could be translated to fieldable systems with 
minimal technical requirements—both in terms of protocol and equipment.  
 
D.  Simplifying assay procedures with simultaneous amplification and detection  
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NAT methodologies differ widely based on the bodily substance sampled and the 
amplification method employed. Recent research has made great strides in achieving reliable 
operation with minimal manipulations, particularly in terms of isothermal amplification 
techniques. Loop-mediated isothermal amplification (LAMP) has become one of the most 
widely researched and commercially automated choices for amplification platforms that are 
amenable to usage at the POC. Early reports in characterizing the tolerance of LAMP for 
biological substances implied that it was more robust and sensitive than PCR[16–18], and 
progress in using LAMP for on-site clinical studies is striding forward[19,20]. A critical 
advancement for clinical LAMP tests, in our reasoning, is the quantitative assessment of 
pathogenic DNA load. The immediate implication is that therapy can be dispensed in the 
appropriate amount at the exact time and place where it is needed. To get right to the nexus 
of whether accurate quantification of blood loads was possible in a field-ready manner, we 
returned to the use of a ubiquitous tool:  a smartphone with a freely available app that could 
perform continuous measurements and process them in an homage to quantitative real-time 
thermal cyclers. 
 
E. The spectrum of big data 
While this work has been devoted to the shift of diagnostic tools towards availability, 
there is another massive movement in biomedicine towards the maximization of 
information. Bioinformatics pushes big data to the extreme with experiments that map whole 
genomes, transcriptomes, and proteomes[21]. The massively parallel sequencing systems of 
NGS exemplify the fast-paced frisson of high-throughput technologies. Frederick Sanger 
developed “first-generation” sequencing in 1977. Shortly after Sanger sequencing was used 
to complete the human genome project, NGS systems found commercial success with the 
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introduction of Roche’s 454 in 2005 (454 Life Science, Roche Diagnostics, Branford, 
CT)[22].  
The revolutionary reach of NGS extends further than the field of genomics. In the study 
of nucleic acid affinity reagents, accessing large numbers of sequences is critical for 
identifying important structure and sequence elements. DNA and RNA molecules that bind 
with high affinity to a specific target are classified as aptamers. The ability of these single 
stranded oligonucleotides to fold into complex tertiary structures begets intricate interactions 
with targets such as peptides, small molecules, and proteins. While the process of generating 
aptamers by systematic evolution of ligands by exponential enrichment (SELEX)[23,24] has 
seen extensions and modifications for tackling “difficult” targets[25–27], there remains an 
inherent bottleneck in characterizing each aptamer’s binding capabilities. Our inquiry was 
whether, by merging the massively parallel genomic investigations of deep sequencing and 
array-immobilized binding, we could obtain aptamers capable of deconvoluting a portion of 
an entire proteome. 
 
F.  Aptamers as a rising rival to antibodies 
A good place to begin talking about the practical application of affinity reagents is with 
the bellwether of the field:  antibodies. The popularity of antibodies as tools for molecular 
recognition can be seen in the workflow of recombinant protein pharmaceuticals. Many 
biopharmaceuticals are the product of recombinant proteins expressed in selected host cells. 
Using host cell lines, which could be prokaryotic (Escherichia coli, E. coli) or eukaryotic 
(Chinese hamster ovary, CHO), for biosynthesis results in a complex, crude material full of 
thousands of proteins that are potential impurities for the final product[28]. For most 
processing purposes, these destabilizing—and potentially toxic—host cell proteins are 
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monitored using multi-analyte enzyme-linked immunosorbant assays (ELISAs)[29]. 
Sandwich-format ELISAs are colorimetric tests that rely on capture antibodies, detection 
antibodies, and a signal-inducing substrate. The requisite polyclonal antibodies incorporated 
into ELISAs are generated by injecting animals (typically goats or sheep) with total cell 
lysate as an immunogen.  
When the purpose of quantifying HCPs in recombinant products is to ensure that the US 
Food and Drug Administration (FDA) standards of less than 100 ppm (w/w) are met, 
ELISAs are inherently limited. Impediments in using ELISAs come from HCPs that do not 
generate immune responses in the animal being immunized, low abundance of produced 
antibody, and nonspecific or oversaturated binding effects[29]. Alongside complications with 
the final assay are electrostatic and hydrophobic variabilities that exist in HCPs throughout 
the production process and clinical application[30]. Even more setbacks emerge when 
considering that polyclonal antibodies themselves take months to develop, vary from batch 
to batch, and exhibit off-target crossreactivity. We reasoned that aptamers—being 
thermostable, inexpensive, and commercially available—could bring about a rebirth for 
HCP testing in recombinant drug development. 
 Typically, selection is meant to drive a random library towards convergence. Reaching 
success with a complex biological mixture such as HCP—specifically, over 6,000 proteins 
are expressed[31] in the case of the CHO genome[32]—depends upon maintaining the 
molecular diversity of the candidate pool. HTS provides the means of reading a million 
aptamer candidate sequences after a minimal number of rounds of directed evolution; DNA 
microarrays act as characterization tools to evaluate aptamer:target binding en masse by the 
tens of thousands. When intertwined, as if in a double helix, these state-of-the-art 
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approaches can form the basis for a rapid, high-throughput aptamer production pipeline 
against proteins with a diverse range of charges, hydrophobicities, and structures.  
 
G.  Objectives and outline 
Today, a burgeoning movement in science has laid the foundations for cross-
connectivity. There are two similarly epochal movements that have given rise to the studies 
presented in this dissertation. Firstly, the decentralization of healthcare has shifted the focus 
of its technologies towards those that can be widely distributed to peripheral care 
providers—to the effect that personalized medicine is becoming the way of the future. 
Secondly, the expansion of big data tools in industry has brought a compulsive reliance on 
high-throughput methods that can automate the collection and subsequent sorting of 
volumes of information. Underlying the new paradigms in both of the aforementioned cases 
is a cross-disciplinary strategy for merging and repurposing available methodologies. 
Herein, we present three novel platforms engineered for rapid, robust, and user-friendly 
applications in biomedicine. 
Chapter II addresses the unfortunate barrier that has separated the worlds of research 
development and practical implementation of NAT. It is entirely appropriate to say that each 
has its own space and place. It is likewise true that each contains aspects of the other, and 
that efforts to develop technology will only be successful if focused on what the end user 
wants. We facilitate point-of-care testing by leveraging ubiquitous technology. Mobile 
healthcare becomes possible—at 1/500th of the cost of laboratory instruments—by 
performing PCR amplification in the heat sink of a standard desktop computer and 
quantifying the end-point signal with an ordinary camera phone. The PC-PCR-Phone (P3) 
system is shown to detect genomic DNA (gDNA) from the causative agent of Chagas 
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disease, Trypanosoma cruzi, in whole blood at concentrations fourfold below the average 
clinical load. 
Chapter III expands upon the idea of nucleic acids as agents of change in field-ready 
diagnostics. Phones once more take a primary position in recording and interpreting the 
results of a DNA amplification assay. The smartphone real time-LAMP (smaRT-LAMP) 
platform presented herein is capable of quantitatively measuring Salmonella enterica 
serovar Typhimurium in whole blood collected from septic mice. SmaRT-LAMP requires 
no manufacture, and distribution is done via a quick app download—all in all, a design 
based on a marriage of something available and something technical to truly achieve results. 
Chapter IV introduces DNA-based affinity reagents as rivals of antibodies in therapeutic 
and diagnostic applications. In order to truly demonstrate their usefulness in the biomedical 
field, aptamers must be more than binders with sensitivity and specificity—they must also 
be functional in biologically relevant environments. The production of therapeutic proteins 
in a typical CHO cell line can release 1,200-1,400 separate HCP proteins (as visualized by 
2-dimensional gel analysis). In order to detect these potentially harmful HCPs by using 
aptamer reagents, we developed a defined set of DNA aptamers to the convoluted gemisch 
of HCPs using an innovative selection strategy of particle display screening, microarray 
characterization, and solid-phase verification of binding. From millions of candidate 
sequences at the height of our aptamer development pipeline, we whittled the final number 
down to several dozen unique binders of diverse HCPs that cover 70% of the CHO proteome 
in their binding capability. 
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Chapter V summarizes the developments presented in this thesis, evaluates the findings 
of each project, and proposes future investigations to further the arc of this thematic story of 
harnessing complementary technologies. 
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Chapter II. Transformation of personal computers and 
mobile phones into genetic diagnostic systems1 
Introduction 
Although advanced molecular diagnostic technologies for the detection of infectious 
diseases such as human immunodeficiency virus (HIV), malaria, and tuberculosis[32],[5] are 
widely available in the developed world, prohibitive costs of equipment and reagents have 
impeded their adoption in the less developed countries (LDCs) in which these diseases are 
most prevalent[33–36]. In contrast, access to certain consumer electronics has surged over the 
past decade in LDCs. For instance, the number of mobile cellular subscribers in the 
developing world rose by more than 600 million between 2010-2011[37] and desktop 
computer penetration has dramatically accelerated since the start of the millenium[38].  
This trend offers an exciting opportunity for leveraging such tools as a means to 
affordably improve healthcare in LDCs. For example, the built-in cameras in mobile phones 
have been adapted as imaging platforms[39,40] for detecting parasites and bacteria[41–43] in 
blood and other clinically relevant samples[44–47]. However, as these methods are 
microscopy-based, they can suffer from poor limits of detection and the challenge of 
differentiating among similar species, subspecies, and strains[48]. Nucleic acid-based genetic 
tests offer higher sensitivity and exquisite specificity[49,50], and several innovative 
approaches have been explored to develop low-cost assays and instruments for genetic 
detection at the point-of-care. For example, Manage et al. achieved streamlined detection of 
BK viruses by performing polymerase chain reaction (PCR) directly in whole blood using 
                                                
1 This chapter is adapted with permission from Walker, Faye M.; Ahmad, Kareem M.; 
Eisenstein, Michael; Soh, H. Tom. Analytical Chemistry 2014, 86, 9326-9241. Copyright 
2014 American Chemical Society. 
  14 
self-contained gel strips[51]. In addition, several groups have demonstrated “sample-in-
answer-out” systems that integrate multiple process steps into a monolithic device using 
microfluidics technology[52–55]. The Landers group pioneered the use of microfluidics for 
genetic analysis[56], isolating and amplifying nucleic acids directly from buccal swabs and 
whole blood for clinical examination[57]. Our group has similarly demonstrated direct 
detection of H1N1 influenza viruses in throat swab samples by integrating magnetic 
separation with reverse transcriptase PCR (RT-PCR) in a disposable device[58]. In practice, 
however, the deployment of these systems in low-resource settings is challenging because 
they often rely on specialized devices and associated instrumentation (e.g. pumps, syringes, 
and detectors) that require skilled technicians for operation. 
We have developed an alternate approach to molecular diagnostics that largely 
eliminates the need for such specialized apparatuses by transforming a desktop PC and a 
mobile phone—devices that are widely available in LDCs—into a highly sensitive platform 
for genetic detection of pathogens. Specifically, we use low-cost software tools to convert 
the PC into a de facto thermal cycler for PCR and configure mobile phones as imagers to 
detect and quantify the resulting PCR amplicons. To our knowledge, this is the first work to 
perform PCR reactions using a PC. In our PC-PCR-Phone (P3) system, a small volume of 
patient blood is added directly to a length of disposable tubing that has been preloaded with 
PCR reagents (Figure 2.1, step 1). The tubing is then placed into the heat sink of the central 
processing unit (CPU), where PCR is performed by using two software programs to 
precisely manipulate the PC’s internal temperature (Figure 2.1, step 2). Subsequently, we 
use a mobile phone camera to image the amplified products, which are quantified according 
to their fluorescence intensity (Figure 2.1, step 3). As a model, we used our P3 system to 
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detect genomic DNA (gDNA) from Trypanosoma cruzi (T. cruzi), the parasitic protist 
responsible for Chagas disease[59,60], which affects over 17 million people worldwide[61,62]. 
We demonstrate direct detection from blood with a limit of detection of 0.1 fg/µL, which is 
well below the average parasitic loads found in clinical samples (0.4 fg/µL). 
 
 
Figure 2.1 P3 assay schematic. First, a small drop of blood obtained via finger prick is added to a 
length of pre-loaded capillary tubing containing the reagents required for PCR. The tubing is then 
inserted between the cooling fins on the heat sink in the computer. Commercial software controls 
CPU usage, cyclically heating and cooling the computer according to a protocol designed to amplify 
any target DNA present. After thermal cycling, the samples are exposed to light and imaged with a 
camera phone. By comparing a histogram of the pixel intensities for the patient sample to control 
samples, the presence or absence of target pathogenic DNA can be determined. 
 
Results and Discussion 
A.  Efficient amplification of genomic DNA in blood using a PC 
PCR amplification of genomic DNA (gDNA) in blood can be hindered by the presence 
of enzymatic inhibitors naturally found in blood or anticoagulants added after sample 
collection[63]. To circumvent this problem, we implemented three key modifications to the 
standard PCR protocol[6] (see Methods). First, we used a step-down (SD)-PCR[64] approach 
that enables specific and high-yield amplification of long template DNA (i.e., gDNA) with 
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reduced byproducts[65]. Second, we adopted a two-temperature PCR scheme, consisting of a 
hot-start followed by alternating hybridization/extension and denaturation steps, that 
simplifies accurate feedback control of the CPU temperature.  
To complete the modified PCR protocol associated with our system, we reduced the 
denaturation temperature to be lower than the maximum temperature for safe, extended CPU 
operation (90 °C). We achieved this by adding dimethyl sulfoxide (DMSO) to our PCR 
mixture, which decreased the melting temperature (Tm) of our primer-template duplex by -
0.6 °C per 1% DMSO (Figure 2.2a). As an added benefit, the addition of DMSO also 
improves yield and reduces undesired byproducts[66,67].  
 
B.  Software-based thermal cycling in a PC  
We installed two software programs that can effectively convert a desktop PC into a 
PCR thermal cycler. The first program (BurnIn Test) is used to rapidly increase the CPU 
temperature through intensive computational operations. The second program (SpeedFan) 
measures the temperature of the CPU in real-time using the built-in thermal sensors common 
to all CPUs, and controls the cooling fan (See Methods for software details). By running 
these two programs, the surface temperature of the CPU can be precisely regulated (Figure 
2.2c, black trace). However, due to thermal resistance between the heat sink and tubing, the 
temperature of the blood sample is lower than that of the CPU. In order to correct for this 
difference, we measured the actual temperature of the sample using thermocouples (Figure 
2.2c, green trace). These data indicate that the difference in temperature between the CPU 
and sample does not vary by more than several degrees, and can be accurately predicted 
with a calibration curve. We established a linear correlation with excellent fit (R2 = 0.992 for 
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heating and 0.995 for cooling, Figure 2.2b) to account for the effect of thermal resistance. 
Since this thermal resistance should not vary across models of PC, we believe our 
calibration curve can be used generally and that it is not necessary to calibrate each PC 
individually. 
 
 
Figure 2.2 With proper temperature calibration and use of additives, DNA is amplified via robust 
thermal cycling within the PC heat sink. a. DMSO reduces melting temperature of double stranded 
DNA. Amplified DNA was diluted to a range of final DMSO concentrations, and the negative first 
derivative profiles are shown. Inset:  linear correlation of Tm (values from maxima of negative first 
derivative curves) and % DMSO. b. By plotting the software-reported CPU temperature versus the 
measured sample temperature, we were able to calibrate the sample temperature to the CPU 
temperature for the heating (red) and cooling steps (blue) separately with best-fit linear regressions. 
c. Temperature traces of the reported CPU temperature (black trace) as recorded by SpeedFan 
software compared with the measured sample temperature (green trace) as obtained by a 
thermocouple probe over the course of three cycles. Each two-step PCR cycle started at a 
temperature of 55 °C for annealing and extension, which was then raised to 83 °C for melting. The 
vertical bars indicate when the CPU (heating, red bars), and fans (cooling, blue bars) were active.  
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C. PC-PCR produces single-length amplicons with high yield 
Our system is capable of simultaneously performing PCR on up to 29 samples with 
reproducible yield and no spurious byproducts. To verify that our PCR protocol only 
generates amplicons of the predicted 100-nt length, we prepared 10 identical samples (20-µL 
each) and monitored the reaction at every other PCR cycle. Visualization with 
polyacrylamide gel electrophoresis (PAGE) clearly showed a single product band that 
matched positive control amplicons obtained with a conventional laboratory thermal cycler 
(Figure 2.3a). We subsequently tested the capacity of our system by performing PCR on 29 
identical reactions distributed across the CPU heat sink. We observed minimal variability in 
amplification (Figure 2.3b), both among the various CPU samples and relative to a control 
amplification performed in a laboratory thermal cycler, as measured by image densitometry 
following PAGE (C.V. < 4%). 
 
 
Figure 2.3 PC-PCR amplification is specific and capable of parallelization. a. To monitor the 
progress of PC-based amplification, we amplified 10 identical samples at different positions across 
the CPU heat sink. One was removed at each cycle, and the resulting products analyzed via gel 
electrophoresis. b. PAGE image showing amplification of a synthetic 100-nt template from reactions 
performed within the PC heat sink alongside controls. Control reactions were performed by carrying 
out 20 cycles of PCR on aliquots of the same negative and positive samples in a commercial thermal 
cycler. Up to 29 reactions may be carried out in parallel. 
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D. Optical detection with a camera phone for DNA analysis 
In order to achieve convenient and quantitative means of readout after amplification, we 
repurposed a standard camera phone into a quantitative DNA detection platform capable of 
measuring as little as 9.6 ag of template DNA. Specifically, we outfitted the camera phone 
with a monochromatic filter to capture fluorescence from a DNA binding dye (see 
Methods). This dye is present in the PCR mix prior to the reaction, and emits green light 
(peak wavelength = 520 nm) under UV excitation when complexed with double-stranded 
DNA amplicons. Using this setup, we were able to clearly differentiate fluorescent signals 
obtained from PCR reactions performed in a conventional thermal cycler with samples 
containing as little as 9.6 ag of template DNA relative to template-free negative control 
samples (Figure 2.4a). Moreover, the detection performance of our camera phone system is 
comparable to that of a laboratory real-time quantitative PCR (qPCR) instrument. Software 
analysis yielded normalized, mean fluorescence intensity values of our camera phone 
images (see Methods), which we plotted as a function of template copy number (Figure 
2.4b, black). We compared these results with the normalized end-point fluorescence values 
obtained from a qPCR instrument (Bio-Rad iQ5) (Figure 2.4b, red). We found that the 
respective performance of these two platforms correlates very closely, with an R2 > 0.99 
(Figure 2.4c), and fall within each other’s error range at low template copy numbers (< 153 
ag). 
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Figure 2.4 Validation of DNA amplicon detection using a mobile phone camera. a. Samples 
containing a range of template molecules were amplified for 30 cycles with EvaGreen, excited by UV 
transillumination, and imaged with a mobile phone camera and 520 nm filter. b. Sensitivity and 
specificity of camera phone detection of amplified DNA in comparison to qPCR end-point detection. 
The normalized fluorescence for 10 independent experiments is plotted versus the log of initial copy 
mass in the reaction. c. Best linear fit shown for correlation between mobile phone camera and 
qPCR end-point fluorescence values for PCR reactions performed on samples initially containing 0 
to 306 ag template. 
   
E. Quantitative detection of T. cruzi using the P3 system 
The average concentration of T. cruzi gDNA in blood samples of patients infected 
with Chagas disease is 0.4 fg/µL[68]. We found that our P3 system can attain sensitivities 
below this level from unprocessed whole blood samples. We performed P3 analysis on 20-
µL samples containing 1 µL whole blood that had been spiked with 0, 0.1, 1, 10 or 100 fg of 
T. cruzi gDNA. After subtracting the background fluorescence from an empty capillary tube, 
we could clearly distinguish reactions that had been performed with as little as 0.1 fg/µL 
gDNA from negative controls (Figure 2.5a). PAGE analysis confirmed that the amplicons 
detected by the P3 system were the predicted 195-bp satellite repeat specific to the 
Diaz1/Diaz2 primer set[69], and that the PCR performance is comparable to that of a 
laboratory thermal cycler instrument (Figure 2.5b). These data suggest that our P3 system 
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should be capable of detecting clinically relevant concentrations of T. cruzi gDNA directly 
from the blood of patients infected with Chagas disease. 
 
 
Figure 2.5 Detection of T. cruzi gDNA in whole blood. a. Images of capillary tubing positioned above 
bar graphs indicating the fluorescence signal obtained from each amount of template gDNA after 
background subtraction. P3 is sufficiently sensitive to reproducibly detect 0.1 fg of gDNA in 1 µL 
whole blood. Error bars were obtained from 4 replicates. b. Gel analysis shows the specific 
amplification of a 195-nt region of tandemly repeating gDNA. A side-by-side comparison of the same 
sample after PCR carried out in a PC or a laboratory thermal cycler shows that PC-PCR can match 
the efficiency of laboratory instrumentation. 
 
Conclusion 
In this work, we report the feasibility of transforming a desktop computer and cell phone 
into a molecular diagnostic system capable of highly sensitive and quantitative pathogen 
DNA detection. These devices are becoming increasingly available in developing countries, 
especially with the aid of humanitarian organizations dedicated to expanding the reach of 
technology in areas of need[70,71]. Using two programs, one free and the other affordably 
priced, we are able to convert a PC into a highly responsive thermal cycler; by adding a 
simple filter, we are likewise able to use a standard camera phone for the quantitative optical 
detection of PCR amplicons. We showed that the P3 system is capable of achieving 
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sensitivities and specificities comparable to that of conventional laboratory instruments at 
1/500th of the cost (Table 2.1). In an initial demonstration with the Chagas disease pathogen 
T. cruzi, we achieved a limit of detection for gDNA that is four-fold below the average 
clinical concentration typically found in patients. There are a number of advantageous 
features inherent to the P3 system. First, sample prep and handling is minimal, as our assay 
is performed directly in blood with no need for mechanical or chemical processing and only 
a brief boiling step required as a prelude to PCR. Additionally, P3 greatly reduces the 
potential for cross-contamination through the use of a single, sealed capillary tube. Finally, 
our system allows multiple samples to be analyzed at once (up to 29 in the current 
configuration), and we envision that it can be adopted for multiplexed detection of multiple 
pathogens in separate capillaries. 
 
	  
Fixed	  Costs	  
	   	  
	  
PCR	   P3	   Vendor	  
Computer	   	  -­‐	  	   	  $-­‐	  	  	  	  
	  Cameraphone	   	  -­‐	  	   	  $-­‐	  	  	  	  
	  Blue	  LEDs	   	  -­‐	  	   	  $8.00	  	   DX	  
Light	  filters	   	  -­‐	  	   	  $33.50	  	   Edmund	  
Thermal	  cycler	  
	  
$7,200.00	  	   	  -­‐	  	   Eppendorf	  
Electrophoresis	  system	   	  $451.00	  	   	  -­‐	  	   Bio-­‐Rad	  
Power	  supply	   	  $350.00	  	   	  -­‐	  	   Bio-­‐Rad	  
Gel	  documentation	  
	  
$10,861.19	  	   	  -­‐	  	   Joyfay	  
Total	  
	  
$18,862.19	  	   	  $41.50	  	  
	   
	  
Marginal	  Costs	  
	   	  
	  
P3	   10	  µl	  rxn	  
	  
	  
Purchase	  price	   Cost/rxn	   Vendor	  
Polymerase	   	  $90.00	  	   	  $0.450	  	   New	  England	  Biolabs	  
Primers	   	  $5.40	  	   	  $0.004	  	   IDT	  
Tubing	   	  $8.00	  	   	  $0.007	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SYBR	  Green	  I	   	  $332.00	  	   	  $0.000	  	   Sigma	  
Control	  DNA	   	  $5.45	  	   	  $0.000	  	   IDT	  
Pipette	  tips	   	  $28.86	  	   	  $0.03	  	   Fisher	  SureOne	  
Total	   	  $469.71	  	   	  $0.49	  	  
	   
Table 2.1 Tally of fixed and marginal costs associated with amplifying and quantifying DNA 
according to standard protocols vs. the P3 approach, which can be carried out at $0.49/reaction. 
 
The sensor technology presented here represents a rapid and facile means of pathogen 
detection in low-resource settings, as indicated by the detection of gDNA in blood. In its 
current iteration, we anticipate that P3 will work primarily as a binary diagnostic assay in 
which an endpoint sample readout is compared to positive and negative controls to 
determine the presence of pathogenic infection. Though beyond the scope of this work, we 
envision that future iterations of system will demonstrate equivalent performance with 
patient blood samples containing intact parasites. Several examples in the literature have 
already established precedents for successful PCR-based detection in blood samples without 
DNA extraction directly from pathogens such as parasites[72], viruses[73], as well as 
trypanosomes[74]. We are therefore confident that P3 can achieve a similar level of 
performance with minimal modifications through techniques such as heat pretreatment and 
optimization of buffers to facilitate the release of gDNA from lysed pathogens. Finally, we 
are currently investigating the potential for adapting P3 for use in more remote regions. As 
resource-limited settings may not have access to reliable power sources for refrigeration or 
computational operation, lyophilized reagents[49] and battery-powered laptops could be 
implemented in future iterations. Laptop CPUs have the added advantage of functioning at 
even higher temperatures than desktop computers with increased portability. Similarly, low-
cost blue LEDs and a blacked-out cardboard box can replace UV transilluminators while 
blocking ambient light for a more inexpensive method of dye excitation (peak absorption 
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wavelength = 500 nm). In sum, we report an innovative method for transforming widely 
available consumer electronics into tools for molecular biotechnology. We believe such re-
purposing may offer versatile strategies for providing molecular diagnostic capabilities to 
resource-limited settings in a cost-effective manner for a diverse spectrum of diseases.  
 
Experimental Section 
A. Materials and Reagents 
All synthetic DNA sequences were purchased from Integrated DNA Technologies 
(IDT). Hot-start polymerase master mix polymerase and nuclease-free water were purchased 
from Promega. PCR validation was performed with a 100-nt single-stranded DNA sequence 
reported previously as Thr-02[24], using primers AGCAGCACAGAGGTCAGATG and 
TTCACGGTAGCACGCATAGG. DMSO was obtained from the American Type Culture 
Collection and used at the concentration indicated. SYBR Green I was obtained from Life 
Technologies and used at 0.625x concentration and EvaGreen was obtained from Biotium 
and used at 1x concentration. Whole blood preserved in EDTA was obtained from 
Bioreclamation. Hemo Klentaq (HKT) polymerase and 5x buffer were obtained from New 
England Biolabs and used in the manufacturer recommended amount. Melting temperatures 
were measured via iQ5 real-time multicolor detection system (Bio-Rad). 
 
B. PC-based PCR 
For initial validation experiments, we used 2 fmol synthetic oligo as template, with 1 µM 
primer in a 50 µL reaction that included PCR mix (containing DNA polymerase, dNTPs, 
buffer), EvaGreen, primers, and 13% DMSO. The optimal DMSO concentration was 
  25 
determined prior to carrying out PCR in a PC by testing the effect of DMSO on dsDNA 
hybridization in the reaction mixture described above. Melting temperatures were 
determined by performing 40 cycles of two-step PCR on the 100-nt template to generate 
double-stranded products in the iQ5. Post-amplification, we carried out a thermal gradient 
beginning at 65 °C and increasing to 85 °C at a rate of 1 °C per minute and dwell time of 10 
seconds, with fluorescence intensity measured every minute. We then calculated the 
negative first derivative of the plot of the resulting melting profile of intensity versus 
temperature. The melting temperature is where this differential plot reaches a maximum, as 
calculated by Bio-Rad iQ5 melt curve analysis. To perform PC-based PCR, the reaction 
mixture was pre-loaded into short capillaries of perfluoroalkoxyl (PFA) tubing. After adding 
template, the capillary tubes were permanently sealed at both ends by epoxy (Devcon) to 
yield contaminant-free testers that are amenable to high-throughput manufacturing. The 
capillary tube was then inserted between the CPU heat sink fins of a Dell Pentium 4 desktop 
computer for cycling. The software used for CPU heating was BurnInTest (Passmark), and 
the fan control and temperature logging were performed by SpeedFan (Almico). The 
external CPU temperature was cycled from 83 °C to 55 °C for 20 cycles by manual control. 
External sample temperature logging and monitoring were performed with a digital 
thermometer (Fluke) and K type thermocouple (Omega). Thermal measurements were 
performed by recording the solution temperature inside capillaries with 50 µL of distilled 
water using a thermocouple probe. At the commencement of each cycle, the Maximum CPU 
temperature test was executed to initiate heating and the CPU fan and case fans were shut 
down using SpeedFan. When the CPU temperature reached 83 °C, the test was ended and 
the fans were set to maximum speed to reduce the CPU temperature to 55 °C.  
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The resulting PCR product was loaded and run on 10% TBE polyacrylamide gels (Bio-
Rad) with a 20bp DNA ladder (Bio-Rad) in 4 °C running buffer. After 15 minutes of gel 
electrophoresis at 300 V, the gels were stained with Gelstar (Lonza) for ten minutes. The 
stained gels were imaged on a Gel Logic System using UV transillumination and a 535-nm 
optical filter (Kodak). The positive control PCR was performed in a commercial thermal 
cycler (Bio-Rad).  
Genomic DNA from T. cruzi (Tulahuen strain) was obtained from ATCC. The sequence 
for the Diaz primer set was CGCAAACAGATATTGACAGA and 
TGTTCACACACTGGACACCAA[75], which target the 195-bp repetitive element in T. 
cruzi nuclear DNA. Capillaries were prepped with 20 µL of reaction mixture containing HK 
Taq polymerase, 0.2 mM dNTPs, 1x buffer, SYBR Green I, 0.2 uM primers, and 13% 
DMSO. After 1 µL human blood was loaded into the capillaries, the capillary tubes were 
sealed on both ends and heated in a boiling water bath for 2 minutes to simulate cell lysis 
and gDNA denaturation steps prior to PC-PCR amplification. From an initial 
annealing/extension temperature of 64.5 °C, the annealing/extension step was reduced by a 
difference of 3 °C every three cycles for the initial step-down cycling phase. After 15 cycles, 
we maintained the annealing temperature at 49.5 °C for 40 cycles to complete the 
amplification phase of SD-PCR (Figure 2.6).  
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Figure 2.6 Two-step SD-PCR protocol for PC-PCR on T. cruzi gDNA. Initial phase is characterized 
by a stepwise decrease of the annealing temperature by 3 °C increments. The second phase of the 
thermal cycling profile operates as a traditional PCR amplification. 
 
C. Post-PCR imaging 
Samples were excited by a UV transilluminator (Kodak). For imaging, a 520±10 nm 
bandpass filter (Edmund Optics) was placed over the mobile phone camera (Samsung) and 
held in place by a silicone case. The phone was situated at fixed distance above the samples 
and the image was captured using the “night mode” option on the Galaxy S camera phone. 
Images were transferred to a computer and analyzed with ImageJ software (nih.gov). 
Rectangular regions of interest were drawn around each sample and the histogram of pixel 
intensities was obtained. Mean histogram values of all samples were then background-
subtracted with the mean histogram value of an empty tube. Average and standard 
deviations are the result of at least four individual trial runs. Data were imported into 
MATLAB and plotted. For relative image analysis, the imsubtract function in MATLAB 
was used to subtract each element in a sample image by the same element in the blank 
(empty) image. From the resulting RGB values, background-subtracted images were 
graphed using the imshow function.  
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Chapter III. Quantitative measurement of genetic 
markers of pathogens in whole blood using a smartphone2 
Introduction 
As the fastest-growing sector within in vitro diagnostics, molecular diagnostic 
technologies are poised to revolutionize the field of healthcare[1–3]. Nucleic acid 
amplification tests provide exquisite sensitivity and specificity for detecting the DNA and 
RNA of pathogenic bacteria, viruses, and parasites. However, various challenges have 
hampered the translation of laboratory-based DNA tests to the point-of-care (POC)[4–6]. 
Oftentimes, molecular testing relies on bulky, costly, and sophisticated equipment to carry 
out numerous processing steps (including sample preparation to extract nucleic acids and 
temperature cycling to amplify the target)[7–9]. Not only are such approaches impractical to 
perform at the POC, many function as end-point assays that do not provide the quantified 
copy-number information that is valuable for understanding disease progression and 
providing accurate diagnosis[10–14]. 
Numerous innovative strategies have shown particular promise in achieving low-cost, 
quantitative DNA detection at the POC[15–17]. For example, Stedtfeld et al. developed a 
miniaturized thermal cycler and phone-based detection system for use in quantifying 
purified genomic DNA (gDNA) of bacterial pathogens found in environmental[18] and 
medical testing sites[19]. Jiang et al. also reported an amplification system that was low-cost, 
solar-powered, and relied on a smartphone for sensing viral DNA[20]. Although these are 
important advances, they have been unable to predict pathogen load from clinically-relevant 
                                                
2 This chapter is in submission for publication as Walker, Faye M.; Fox, Gary N.; 
Heithoff, Douglas M.; Mahan, Michael J.; Soh, H. Tom. Quantitative measurement of 
genetic markers of pathogens in whole blood using a smartphone.  
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samples without relying on sample processing procedures that reduce throughput and 
accuracy[8,21]. Achieving sensitive, quantitative detection of pathogenic DNA at disease-
relevant concentrations directly from raw, unprocessed samples remains an elusive goal[22–
26]. 
Here, we report a smartphone-based diagnostic platform (“smaRT-LAMP”) that requires 
minimal resources to provide DNA template copy-numbers from bloodborne pathogens in 
whole, crudely lysed blood samples. For convenient use at the POC, we developed an 
Android phone application (“Bacticount”) that continuously photographs the DNA 
amplification reaction, mathematically processes the images, and automatically performs a 
customized algorithmic analysis that provides the target DNA copy-number without 
operator intervention. To the best of our knowledge, this is the first study that utilizes the 
camera feature of smartphones to achieve quantitative DNA analysis in real-time. As a 
proof-of-concept, we used the smaRT-LAMP system to detect as low as 100 colony-forming 
units (CFU) of the bacterial pathogen Salmonella enterica var. Typhimurium (S. 
Typhimurium) from a single µL of blood in under an hour. We further demonstrated the 
successful application of our platform for the rapid and sensitive detection of Salmonella 
genomic DNA (gDNA) derived from the whole blood of septic animals[27,28]. The sensitivity 
of our smart-LAMP system matches that of a laboratory-based (Bio-Rad iQ5) quantitative 
real-time PCR (qRT-PCR) instrument while substantially reducing the cost and size, and 
could have a transformative impact in global health applications for limited-resource settings 
with high disease burden[29]. 
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Results and Discussion 
A. Overview of the smaRT-LAMP system 
The smaRT-LAMP system is designed to quantitatively detect bacterial pathogens (via 
real-time optical detection of DNA amplification) directly from blood samples using 
minimal resources. To start, the blood sample is lysed in a straightforward, single-step 
process. This crude lysate is combined with a pre-made LAMP reaction mixture that will 
generate a fluorescent signal in response to template amplification (see Experimental 
Section). Our protocol is convenient, reproducible, and maximizes DNA recovery because it 
does not require a separate nucleic acid extraction or purification. The prepared LAMP 
samples are placed in an inexpensive setup consisting of a sample tube holder (that can 
simultaneously accommodate up to 12 samples), a single-temperature heat block, and an 
LED light source (Figure 3.1a). In comparison to a conventional $35k real-time thermal 
system, the entire cost for our setup is US$96.  
To automatically obtain copy-number information, we implemented our custom 
Bacticount smartphone application. The Bacticount app was developed by the authors and is 
freely available through the Google Playstore for phones using the Android operating 
system (see Experimental Section). The operations performed by the Bacticount app are 
described in Figure 3.1b. Briefly, it performs image analysis to recognize the location of 
each sample tube and obtains its average fluorescence every 10 seconds. With this 
information, the app employs a “coarse derivative” algorithm to transform the fluorescent 
data into a time-to-threshold parameter (Tt) that is linearly related to the logarithm of the 
template DNA copy number[30]. We developed this mathematical algorithm to be quickly 
completed using a smartphone’s processing capabilities and to be robust against fluctuations 
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in background fluorescence, camera recalibrations, and shifts in the relative position 
between the sample and the smartphone camera (see Supplementary Discussion for further 
explanation). Finally, the Bacticount app displays the calculated DNA quantities from 
bacterial pathogens for all 12 samples. 
 
 
Figure 3.1 The components for smaRT-LAMP detection are a combination of reaction-independent, 
commonly available materials and reaction-dependent inputs that are determined by the user. a. 
Minimal instrumentation is required, as the platform consists of basic elements. LEDs illuminate the 
samples, which give off a fluorescent signal that is detected by a smartphone camera outfitted with a 
green filter. The system is closed off from background light with a cardboard box that is painted 
black. Once the samples, LEDs, and phone lens have been aligned, the user will be guided through 
the details of starting a test through a tutorial provided on the Bacticount app. b. Diagram 
demonstrates the algorithm behind the image processing and DNA quantitation carried out by the 
Bacticount Android app in the course of a smaRT-LAMP run. A photo obtained from the camera 
function of a smartphone is cropped to isolate an individual sample. A histogram of RGB signals is 
used to determine the average intensity in the green channel. Raw fluorescent intensities are 
collected in this manner every 10 seconds for 70-minute run. The data is smoothed before taking the 
coarse derivative of average fluorescence over the full time period. The maximum of the resulting 
coarse derivative (roughly analogous to the point of fastest rate of increase) gives the Tt. If the 
concentration of the sample of interest is known, the Tt will be related to the log of the concentration 
to form a standard curve; otherwise, the concentration of an unknown test sample can be back-
calculated from a reference curve. 
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B. Accuracy of quantitative profiling 
The performance of smaRT-LAMP matches that of a state-of-the-art Bio-Rad iQ5 qRT-
PCR instrument in determining precise template copy numbers from pathogenic gDNA. We 
first determined the detection sensitivity and specificity of smaRT-LAMP by detecting S. 
Typhimurium using a set of six LAMP primers designed to target the highly conserved recF 
gene of S. enterica[31,32]. These primers are specific for the model organism, showing no 
interaction with gDNA from three unrelated parasites in qRT-PCR, melt curve analysis, and 
qRT-LAMP tests (Figure 3.2). 
 
 
Figure 3.2 Assessment of the sensitivity and specificity of the outer primers, inner primers, and loop 
primers designed to target the recF gene of Salmonella. a. Schematic of SD-PCR temperature 
cycling protocol used in amplifying a 190-bp region of the S. Typhimurium genome. b. Outer primers 
were defined for use in the LAMP reaction, but are applied to SD-PCR to test specificity for the recF 
gene. Real-time monitoring by EvaGreen shows efficient amplification without spurious by-products. 
A Bio-Rad qRT-PCR instrument was used to carry out the SD-PCR protocol in a on samples with 
100-fold dilutions of template gDNA. The limit of sensitivity is 0.5 pg, as illustrated by the 
amplification quantitation results. c. The specificity is such that only one amplicon is generated, as 
illustrated by the melting curve results. d. Performing a LAMP specificity test on a Bio-Rad iQ5 qRT-
PCR machine shows that the six primers do not interact with the gDNA of other pathogens. In the 
presence of three non-target strains of pathogenic genomic DNA, only the desired Salmonella 
species is amplified. e. The LAMP primers used to amplify S. Typhimurium were adapted from 
Patterson et al.[31], with the addition of loop primers in the manner of Nagamine et al.[33] F1c indicates 
the complement sequence of the F1 primer region; similar notation is used for B2c and B3c. The 
recF gene target is conserved in the vast majority of Salmonella serovars.  
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As shown in Figure 3.3a, the Tt values and resulting copy-number data from smaRT-
LAMP and the standard iQ5 qRT-PCR instrument exhibit minimal differences over a wide 
range of template gDNA from 100 ng down to 10 pg. The observed Tt values were highly 
linear with respect to the logarithm of input gDNA in both systems of instrumentation (lines 
of best fit with regression coefficients both R2 > 0.99 provided in Figure 3.3b). Results were 
accurate and reproducible, as the standard curve from smaRT-LAMP produced average 
values that were within 4% error of the theoretical concentrations (Table 3.1). This strongly 
demonstrates that the smaRT-LAMP platform could replace a conventional real-time 
thermal cycler at reduced operative costs. 
 
Figure 3.3 Real-time quantification verified with Salmonella gDNA. a. Real-time signal response 
from a Bio-Rad iQ5 or smaRT-LAMP system. For the iQ5, fluorescence was measured at 10-s 
intervals by the cycler, extracted from the optical system software without any additional corrections, 
and normalized in MATLAB by a custom script. For the smaRT-LAMP platform, the Bacticount app 
was used to record the green emission of the fluorescent signal every 10 s, calculate normalized 
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signals, and output a .pasc file of the resulting values. b. Signal response of S. Typhimurium gDNA 
with recF primers linearly correlates to the log of initial template quantities. Line of best fit from least-
squares regression is shown in plot of Tt (red, Bio-Rad iQ5 qRT-PCR system and blue, smaRT-
LAMP system) vs. log[gDNA]. The plot of smaRT-LAMP (blue squares) and iQ5 (red circles) gDNA 
amounts calculated from the best-fit lines show that the measured pg values correlate closely with 
each other, and with the predicted values indicated on the x-axis. All readings are from 4 
determinations with the same sample. 
 
 
theoretical log[pg] 5 4 3 2 1 
iQ5 qRT-LAMP experimental Tt 8.83 10 10.83 11.67 13.17 
 
  9.33 9.83 10.83 12 13.17 
 
  9 10.17 10.83 11.5 13 
 
  9 9.83 10.83 11.83 12.83 
 
  0.21 0.16 0 0.22 0.16 
 
mean experimental Tt 9.04 9.96 10.83 11.75 13.04 
 
mean experimental log[pg] 4.91 3.98 3.09 2.16 0.85 
 
% error of mean 1.79 0.48 3.11 8.15 14.77 
smaRT-LAMP experimental Tt 9.28 10.78 12.44 13.78 15.94 
 
  8.94 11.11 12.28 14.28 16.11 
 
  9.11 10.61 12.44 13.78 15.61 
 
  9.11 10.28 11.61 14.11 15.11 
 
  0.14 0.35 0.4 0.25 0.44 
 
mean experimental Tt 9.11 10.69 12.19 13.99 15.69 
 
mean experimental log[pg] 4.96 4 3.09 2 0.96 
 
% error of mean 0.85 0.09 2.87 0.08 3.83 
 
Table 3.1 Initial characterization of smaRT-LAMP technique with purified S. Typhimurium gDNA. The 
log of template quantity was determined by using the coarse derivative algorithm to calculate Tt after 
performing qRT-LAMP in a standard iQ5 instrument, or in the low-cost smaRT-LAMP setup. For 
each known concentration of gDNA, four replicate tests were carried out. Calculations assume that 
the theoretical log[pg] represents the total amount in 1 µL of input sample. 
 
C. Detection of bacterial pathogens in whole blood  
To accurately detect nucleic acids from target pathogens, we formulated a procedure that 
could generate amplifiable gDNA in a crude input sample of whole, lysed blood. 
Endogenous, blood-based components such as Immunoglobulin G (IgG) or hemoglobin can 
give off high background signals, quench fluorescent dyes, and inactivate the polymerase in 
nucleic acid amplification tests[13,34–37]. As LAMP has shown tolerance to inhibitors in 
crudely processed samples, including case studies with blood[38–45], we bypassed nucleic 
  38 
acid extraction for a single NaOH[46]/detergent[47]/heat[48] step that would lyse cells by both 
physical and chemical means. We prepared serial dilutions of cultured ST14028 cells, 
minimally processed the samples as such, and directly added the lysate to pre-prepared 
LAMP reagents (Figure 3.4a). Fluorescent signals from qRT-LAMP were used to obtain Tt 
values in the iQ5 and smaRT-LAMP platforms (time-course curves can be found in Figure 
3.5a). The resulting Tt parameters were linear over several log orders, from 102 CFU 
through 107 CFU of ST14028. Furthermore, sensitivities and linearities were 
indistinguishable between the conventional method and our assay (as shown in Table 3.2 
and Figure 3.4b with correlation coefficients of R2 > 0.99 in the least-squares fit for each 
case). 
 
  39 
 
Figure 3.4 Detecting gDNA derived from crude extract of bacteria. a. Template samples were lysed 
with a single-step alkaline and heat lysis, added to LAMP reagents, and amplified at 65 °C. b. 
Amplification of gDNA from ST14028 cells in buffer is carried out in a Bio-Rad iQ5 thermal cycler or 
the smaRT-LAMP platform. Tts are calculated by MATLAB in the case of the iQ5 (red), or by the 
Bacticount app in the case of smaRT-LAMP (blue). Times are plotted against log of known CFU to 
obtain standard curves with regression coefficients as shown. Measured bacterial counts in buffer 
are back-calculated from the standard curves, giving numerical values for smaRT-LAMP (blue 
squares) and qRT-LAMP (red circles) that are approximately equal to the expected values indicated 
along the x-axis. c. Observed same limits and linearity from iQ5 or smaRT-LAMP standard curves 
after amplification of gDNA derived from bacteria spiked into whole blood. The experimental smaRT-
LAMP (blue squares) and qRT-LAMP (red circles) bacterial counts in blood calculated from the Tts 
are within range of each other, in addition to being close to the known input concentrations shown 
along the x-axis. All readings are from 4 determinations with the same sample. 
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theoretical log[CFU] 7 6 5 4 3 2 
iQ5 
qRT-
LAMP experimental Tt 8.67 9.33 11.33 11.33 12.67 13.33 
 
  8.5 9.5 10.67 11.83 12.33 12.5 
 
  8.67 10 10.83 11 12.33 13.33 
 
  8.67 9.33 10.33 11.67 12.67 13.67 
 
  0.08 0.32 0.42 0.37 0.19 0.5 
 
mean experimental Tt 8.63 9.54 10.79 11.46 12.5 13.21 
 
mean exp. log[CFU] 7.07 6.09 4.75 4.03 2.91 2.16 
 
% error of mean 0.96 1.42 5.1 0.79 2.84 7.8 
smaRT-
LAMP experimental Tt 9.36 10.03 12.7 12.2 12.53 14.55 
 
  7.49 10.51 10.18 14.2 13.7 15.55 
 
  9.01 9.51 11.03 10.85 16.38 13.7 
 
  8.01 9.01 12.19 11.69 12.19 13.53 
 
  0.87 0.65 1.14 1.42 1.9 0.93 
 
mean experimental Tt 8.47 9.77 11.52 12.23 13.7 14.33 
 
mean exp. log[CFU] 7.13 6.07 4.62 4.04 2.83 2.31 
 
% error of mean 1.92 1.13 7.6 0.93 5.69 15.58 
Table 3.2 Limits of detection for smaRT-LAMP and Bio-Rad iQ5 qRT-LAMP in calculating log of 
initial template quantities from a known concentration of S. Typhimurium in buffer. Four replicates 
were performed for each starting concentration indicated. Calculations assume that the theoretical 
log[CFU] represents the total amount in 1 µL of input sample. 
 
We next adapted the assay to amplify gDNA derived from known concentrations of 
ST14028 cells spiked into whole mouse blood. To avoid high background fluorescence from 
red blood cells, we diluted the input blood template by a factor of 120x into the alkaline 
buffer used for our NaOH/detergent/heat processing step; the diluted and lysed samples 
were then used directly for qRT-LAMP in an iQ5 or smaRT-LAMP. Similar results were 
achieved for the dynamic range in spiked blood as with Salmonella bacteria in buffer. 
Detection sensitivity was 102 CFU in either the Bio-Rad iQ5 or smaRT-LAMP platform 
(Figure 3.4c), and no signal was observed from uninfected blood used as a negative control 
(Figure 3.5b). Notably, this limit corresponds to a bacterial load in blood of 105 CFU/mL, 
which is within the relevant range of blood concentrations found in septic mice during late 
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stage infection[31]. Our results also highlight the accuracy of smaRT-LAMP:  average 
measured bacterial counts, based on the regression curve in Figure 3.4c, demonstrate less 
than 8% error with respect to the theoretical values (Table 3.3). This demonstrates the 
ability of smaRT-LAMP to perform quantification of parasite load in a clinical setting. 
 
 
 
Figure 3.5 Real-time amplification curves obtained from crudely lysed S. Typhimurium as template, 
with error bars from four independent experiments. a. Amplification from the recF gene of gDNA in 
crude, lysed S. Typhimurium, as detected by a Bio-Rad iQ5 thermal cycler or smaRT-LAMP. Initial 
template stocks of indicated CFU are diluted, heated, and added to LAMP reagents. Signal from 
FDR is recorded every 10 s in an iQ5 for real-time plot on left. Raw data is exported and normalized 
in MATLAB. Smartphone-based smaRT-LAMP platform monitors emission from FDR at 520 nm 
every 10 s for real-time plot on right. b. Amplification of gDNA from S. Typhimurium spiked into 
whole mouse blood using qRT-LAMP or smaRT-LAMP shows clinically relevant levels of detection. 
Each curve obtained with S. Typhimurium indicates the concentration of the template that was 
initially spiked into whole, uninfected mouse blood. Template samples were lysed, added to LAMP 
reagents, and monitored at 65 °C in an iQ5 (left) or in smaRT-LAMP (right), and data processed as 
above.  
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theoretical log[CFU] 7 6 5 4 3 2 
iQ5 
qRT-
LAMP experimental Tt 8.83 9.5 10.5 11.5 12.83 14.67 
 
  8.83 9.67 11.17 11.67 12.83 14.17 
 
  9 9.67 10.83 12 12.83 13.5 
 
  9.17 9.83 11 12 13.17 14.5 
 
  0.16 0.14 0.28 0.25 0.17 0.52 
 
mean experimental Tt 8.96 9.67 10.88 11.79 12.92 14.21 
 
mean experimental 
log[CFU] 6.8 6.14 5 4.13 3.07 1.86 
 
% error of mean 2.8 2.28 0.05 3.33 2.42 7.21 
smaRT-
LAMP experimental Tt 6.94 7.78 9.11 9.78 12.28 11.94 
 
  6.78 7.61 9.44 9.78 11.78 11.44 
 
  6.78 8.11 9.28 9.61 10.11 11.61 
 
  6.44 7.61 8.44 9.94 10.11 12.11 
 
  0.21 0.24 0.44 0.14 1.13 0.3 
 
mean experimental Tt 6.74 7.78 9.07 9.78 11.07 11.78 
 
mean experimental 
log[CFU] 7.06 6.05 4.79 4.1 2.85 2.16 
 
% error of mean 0.83 0.76 4.2 2.54 5.1 7.89 
Table 3.3 Concentrations of S. Typhimurium spiked into blood, as assessed by smaRT-LAMP or by 
a laboratory iQ5 instrument. The log of each initial template quantity was derived via the coarse 
derivative analysis in four determinations for each indicated concentration of S. Typhimurium in 
blood. Calculations assume that the theoretical log[CFU] represents the total amount in 1 µL of input 
sample. 
 
D. Quantitative diagnosis of Salmonella in a murine model of Typhoid fever 
We used the murine typhoid fever pathogen S. Typhimurium to evaluate the 
performance of smaRT-LAMP as a diagnostic platform. Five mice were intraperitoneally 
infected with a lethal dose (103 CFU) of S. Typhimurium parasites. During late stage sepsis 
(day 5 post-infection), we collected tail blood for smaRT-LAMP analysis. The measured Tt 
parameters were transformed into numbers of bacteria using the predetermined reference 
curve of Tt vs. log[CFU] in Figure 3.4c. Upon obtaining parasitemia levels via smaRT-
LAMP, we performed a comparative analysis with CFU derived from direct colony counting 
upon plating, as well as qRT-LAMP analysis with the iQ5 (Figure 3.6). As shown in Table 
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3.4, the log[CFU/mL] values obtained with our smaRT-LAMP approach were reproducible 
within replicates and consistent throughout the experiment with those from the Bio-Rad iQ5.  
In all cases, the two sets of LAMP-based measurements were within 2% difference of each 
other. Moreover, we established that smaRT-LAMP can differentiate negative from positive 
cases of infection down to a limit of 2.5 x 104 CFU/mL with a rapid turnaround time of 50 
minutes per sample run. 
 
 
 
Figure 3.6 Comparison of smaRT-LAMP, iQ5 LAMP, and direct colony counting detection methods 
from a representative population of Salmonella derived from whole blood of septic mice. ST 14028 
bacterial cells are from overnight cultures. a. A dose of 1,000 CFU is used to infect mice, which 
reach late stage sepsis at approximately 5 days post-infection. b. Mouse blood collected from the tail 
vein is loaded into the smaRT-LAMP platform (blue triangles), a Bio-Rad iQ5 qRT-PCR (red circles), 
or reserved for plating and direct colony counting (black bars). Black line represents the mean value 
from 5 independent runs. Similar limits of sensitivity are observed for all measurements, with 
predictive values of 1x105 - 1x106 CFU/mL if biological culture is taken as the gold standard. 
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Table 3.4 The parasitemia level of each mouse at late-stage infection as assessed by smaRT-LAMP 
or qRT-LAMP in a Bio-Rad iQ5. The log of initial template quantities were computed by converting Tt 
parameters from a coarse derivative analysis into CFU/mL values via the standard curves obtained 
from measurements with spiked blood samples. Five determinations were made with the same 
sample of septic mouse blood for each of the five mice infected with Salmonella. Errors of the 
theoretical log[CFU/mL] results are from comparison with direct colony counts. 
 
Conclusion  
In the current study, we have designed a nucleic acid amplification system capable of 
reliably detecting and quantifying bloodborne pathogens in real time. Our demonstration 
with non-typhoidal salmonellae, the leading cause of death from food-borne illnesses in the 
United States[49–51], indicates that smaRT-LAMP is a rapid (signal saturation observed in 
less than 20 minutes), sensitive (102 CFU S. Typhimurium per µL of spiked blood), and 
robust (functions directly on blood specimen) tool for the accurate detection of life-
threatening pathogens. The application of smaRT-LAMP to POC monitoring could further 
global efforts to properly diagnosis salmonella infections and initiate effective therapies, 
 
direct colony counting of 
log[CFU/mL] 5.77 5.86 5.56 5.52 5.48 
iQ5 qRT-
LAMP experimental log[CFU/mL] 6.13 6.42 6.91 8.09 5.81 
 
  6.13 6.42 6.91 8.09 5.81 
 
  6.13 6.42 6.91 8.09 5.81 
 
  6.13 6.42 6.91 8.09 5.81 
 
  6.13 6.42 6.91 8.09 5.81 
 
mean experimental log[CFU/mL] 6.13 6.42 6.91 8.09 5.81 
 
% error of mean 6.24 9.56 24.28 46.56 6.02 
smaRT-
LAMP experimental log[CFU/mL] 5.58 6.64 6.52 8.15 4.55 
 
  5.58 6.64 6.52 8.15 4.55 
 
  5.58 6.8 6.52 8.15 4.22 
 
  5.74 6.8 6.52 8.15 4.22 
 
  5.74 6.8 6.68 8.31 4.55 
 
mean experimental log[CFU/mL] 5.64 6.74 6.55 8.18 4.42 
 
% error of mean 2.18 14.95 17.84 48.22 19.38 
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thus reducing the excessive use of inappropriate antibiotics that leads to untreated morbidity 
and bacterial resistance[29,52,53]. Our system offers results in minutes, rather than the timeline 
of 2-5 days required for conventional bacterial culture, and has the added advantage of being 
a highly automated platform with ultralow costs per assay (less than $2; see Table 3.5).  
 
Fixed Costs 
  
 
iQ5 qRT-
LAMP 
smaRT-
LAMP Vendor 
Smartphone  -   $-    
 Sample holder  -   $65.00  Light Labs 
Blue LEDs  -   $6.33  Deal eXtreme 
12-V battery  -   $3.97  Home Depot 
Green light filter  -   $3.95  Battery Junction 
Hot plate  -   $17.00  Aroma Housewares 
Real-time thermal cycler 
 
$34,950.00   -  Bio-Rad 
Total 
 
$34,950.00   $96.25  
 
    
 
Marginal Costs for smaRT-
LAMP Assays 
 
 
Purchase 
price Cost/rxn Vendor 
Polymerase  $208.00   $0.21  New England Biolabs 
Primers  $0.93   $0.01  IDT 
Buffer  $52.73   $0.66  In-house 
FDR  $128.00   $0.64  SA Scientific 
Sample tube  $99.00   $0.10  Bio-Rad 
Sample lid  $23.04   $0.02  Bio-Rad 
Total for 50 µl rxn  $1.64  
  
Table 3.5 Comparison of commercial and in-house costs of performing qRT-LAMP. Note that prices 
can vary according to vendor and purchaser. Tally represents necessary consummables and 
reagents, but does not account for labor. 
 
With respect to other analytical techniques in the literature, our protocol attains 
analogous sensitivities for numerical counts of bacterial pathogens. A recent example of a 
smartphone-based platform for fluorescent microscopy detection of S. Typhimurium, 
developed by Fronczek et al., demonstrated the detection of 105 CFU/mL of gDNA spiked 
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into diluted blood[54]. In real-time measurements of S. Typhimurium on an electrochemical 
device, Patterson et al. demonstrated a sensitivity of 103 CFU per sample of infected mouse 
blood[31]. Our own platform has a lower bound of 102 CFU in a single-tube reaction 
performed on unpurified blood with minimal chemical treatments. In blood samples from 
infected animals, this corresponded to a lower detection limit of 2.5 x 104 CFU/mL of 
bacteria. Furthermore, smaRT-LAMP provides amplification test results in real time—with 
the same reliability, sensitivity, and specificity as a commercially available qRT-PCR 
system—through the novel application of a standardized “coarse derivative” model of qRT-
LAMP. 
Our method covers a wide dynamic range with diagnostically relevant limits of 
detection, correlates well with measurements from laboratory instruments, and has the 
potential to guide prognostic decisions at the POC. Even with these positive attributes, the 
smaRT-LAMP system could be further enhanced to maximize its functionality. We 
anticipate that the high pixel count of cameraphone optics will make it possible to increase 
throughput without loss of signal resolution. Likewise, we are exploring ways to standardize 
the setup to encase a heat source, light element, and viewing aperture through 3-D printing 
or otherwise low-cost fabrication techniques. Looking further to the future, today’s 
availability of whole-genome databases[50,55] will make it possible to adapt smaRT-LAMP to 
sense a wide variety of other bacterial species and viruses in the detection, profiling, and 
treatment of bloodstream infections. 
 
Experimental Section 
A. Amplification reactions 
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Previously designed primers targeting the recF gene of S. Typhimurium[31] were employed 
with the addition of loop primers chosen to accelerate the reaction by priming strand 
displacement synthesis[33]. The set of primers consisted of two outer (F3 and B3), two inner 
(FIP and BIP), and two loop primers (Loop-F and Loop-B). All synthetic oligos were 
purchased from Integrated DNA Technologies (Coralville, IA). Stepdown (SD)-PCR[56,57] 
was used to validate F3 and B3 primer sensitivity. Experiments were performed with an iQ5 
qRT-PCR instrument (Bio-Rad cat. no. 170-9780) by adding calibration samples containing 
dilutions of template to a reagent mixture of 500 nM each F3 and B3, 1x EvaGreen (Biotium 
cat. no. 31000), 1x GoTaq PCR Master Mix (Promega cat. no. M7122), and 5 µM MgCl2 
(Sigma-Aldrich cat. no. M1028). Temperature cycling was carried out according to the 
following protocol in thirty second intervals:  from an initial annealing temperature of 68 °C, 
the temperature of this step was reduced by 2 °C every 2 cycles for the initial stepdown 
cycling phase. After 10 cycles, we maintained the annealing temperature at 58 °C for 40 
cycles of 30 s at 94 °C, 30 s at 58 °C, and 30 s at 72 °C to complete the amplification phase 
(Figure 3.2a). LAMP reactions were carried out in 50-µL volumes containing 0.2 µM each 
F3 and B3, 1.6 µM each FIP and BIP, 0.8 µM each Loop-F and Loop-B, template (variable), 
0.1 µL Triton X-100, 2 µL Bst 2.0 polymerase (New England BioLabs cat. no. M0537), 25 
µL Loopamp Reaction Mix (SA Scientific cat. no. E-2040; also prepared in-house with no 
differentiation in outcome[25,58]), 0.8 µL Fluorescent Detection Reagent (FDR, SA Scientific 
cat. no. E-2210), and nuclease-free distilled water (SA Scientific cat. no. E-2040). All 
amplifications were carried out at 65 °C for 60 minutes, at which point the temperature was 
increased to 85 °C for 5 minutes in order to deactivate the polymerase. The smaRT-LAMP 
platform uses a signal-on approach to quantitatively detect specific DNA sequences. 
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Measurements of amplicons are based on the enzymatic activity of Bst polymerase, which 
releases pyrophosphate ions as a by-product of DNA synthesis. These pyrophosphate ions 
complex with divalent manganese ions, releasing the FDR (which contains the fluorescent 
indicator calcein) from quenching by Mn+2. 
 
B. Preparation of template DNA 
Genomic DNA from S. Typhimurium strain LT2 was purchased from ATCC 
(Salmonella enterica subsp. enterica serovar Typhimurium ATCC-700720). For each 50 µL 
LAMP reaction, 5 µL of prepared gDNA stock was used as template. Bacterial cultures were 
prepared from virulent S. Typhimurium reference strain ATCC 14028 (CDC 6516-60)[27,28]. 
For DNA extraction of bacterial samples, a simplified alkaline treatment was used[46]. A 1 
µL sample was vortexed for 15 seconds with 49 µL of 50 mM NaOH and 0.5% Triton X-
100 and heated at 99 °C for 10 minutes. After cooling on ice, 8 µL of 1 M Tris-HCl (pH 7.5) 
was added to neutralize. For each 50 µL LAMP reaction, 25 µL of this diluted, neutralized 
bacteria solution was used as template. In the case of blood samples, steps were performed 
similarly with the addition of increased sample dilution and vortex mixing. Blood was 
diluted in a 1:120 ratio with 50 mM NaOH[48] and 0.5% Triton X-100[47]; vortexed for 20 
seconds, then an additional 10 seconds; incubated at 99 °C for 10 minutes; snap-cooled on 
ice; neutralized by addition of 19.2 µL 1 M Tris-HCl; then spun down by centrifugation at 
4k RPM for 5 minutes. For each 50 µL LAMP reaction, 25 µL of this diluted, neutralized 
blood solution was used as template. 
 
C. Salmonella infection and blood sampling 
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Bacterial cells derived from overnight cultures were resuspended in 0.15 M NaCl and 
delivered to mice via intraperitoneal (i.p.) injection[28]. Whole blood (25 μL) from the tail 
vein of infected mice was collected on day 5 post-infection into BD Microtainer tubes with 
K2-EDTA (Becton-Dickinson, cat. no. 365973). 
 
D. MATLAB analysis algorithm 
To develop an image processing pipeline, MATLAB was initially used on the optical 
measurements from an iQ5 qRT-PCR time-course plot of fluorescence. Background 
fluorescence is subtracted from the data using the fluorescent values prior to the first 
inflection point of the curve. Normalization is performed by scaling the fluorescence after 
the second inflection point of the background-subtracted data so that all values are between 
0 and 1. After this basic normalization, we use a processing algorithm (described in detail in 
the Supplementary Discussion section) to find the maximum of the derivative taken over a 
coarse time stepper. The resultant Tt value is linearly related to the logarithm of the input 
concentration. 
 
E. Hardware of smaRT-LAMP platform 
All experiments were performed in low-profile 0.2-mL PCR strips (Bio-Rad cat. no. 
TLS-0801) covered with optical flat strips (Bio-Rad cat. no. TLS-0803). For thermal 
incubation, tubes were placed in an aluminum sample block (LightLabs cat. no. A-7079) on 
a hot plate. A cardboard box large enough to cover the hot plate was painted black and two 
flexible cables of 96W, 480 nm, 672 lm, 96-LEDs (DealeXtreme cat. no. 180563) were 
affixed to the inside top cover of the box. Lights were illuminated with a 12 V battery. A 
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Motorola Moto X 2nd Generation phone (Motorola Mobility, LLC) was outfitted with a 
520±10 nm bandpass filter (Edmund Optics cat. no. 65-699) for visual detection of emitted 
green light. 
 
F. Development of Bacticount Android application 
The Bacticount smartphone application was built on a Motorola Moto X 2nd Generation 
(Motorola Mobility, LLC) phone using the developer tools in Android Studio (Android). For 
implementation, the app is downloaded from the Google Play Store and installed via the 
“OpenCV Manager” application (employed to handle complex algorithms such as image 
rendering, histogram generation, and back-calculations). Upon opening the app, the user is 
initially presented with a step-by-step tutorial. Following the tutorial, the user is given a 
choice to record either a standard curve (reference point calibration) or test reaction. 
Additionally, the user can view previously processed reactions.  
In the case of running a reference or test reaction, the app launches a specialized 
viewfinder allowing the user to carefully center the reaction vials in the viewframe of the 
phone’s camera such that their intensity can be analyzed over time. Upon hitting “record 
amplification,” the application proceeds to take one photograph of the amplification reaction 
every 10 seconds over the course of a 70-minute period. The app performs image processing 
for each of the vials outlined in the viewfinder to extract the average green intensity of each 
pixel, which is stored in a matrix. For the “standard curve run” option, the software also 
prompts the user to align each reference sample with ta provided sample map so that the 
input the starting concentrations of DNA are known. The standard curve is determined 
through a linear regression fit of Tt vs. log[conc], which is stored as a reference .pasc file for 
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determining the results in future tests. If the user has selected the “sample run” option, the 
app will prompt the user to choose a standard curve that has been recorded as outlined in the 
previous section with known references. After data processing and analysis (described in 
detail in the Supplementary Discussion section), the Tts of unknown test samples are 
related to their initial concentrations via the standard curve. On its final screen, the app 
displays the number of copies of DNA in each reaction vial. The numerical results and 
collected time-stamped photos are saved as a .parr file and as .jpeg files, respectively, which 
may be extracted by the user to any computer; alternatively, the digitally-processed results 
can be uploaded to a central server where a wireless internet connection is available. 
All runs are designed with a built-in feature that determines whether amplification has 
been successful based on the behavior of positive and negative controls. The positive control 
must fulfill the criteria of having an increase in fluorescent signal that signifies complete 
amplification, determined in comparison to the negative control. If the positive behaves 
worse than the negative, the user is notified that the run is a failure. The negative should not 
amplify at all, and the user is likewise alerted when an increase in amplification is observed.  
 
G. Ethics statement  
All animal experimentation was conducted following the National Institutes of Health 
(NIH) guidelines for housing and care of laboratory animals and performed in accordance 
with institutional regulations after pertinent review and approval by the Institutional Animal 
Care and Use Committee at the University of California, Santa Barbara. 
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Supplementary Discussion 
In the LAMP reaction, Bst polymerization occurs in a highly parallel and autocyclic 
fashion that lends the real-time fluorescent output a sigmoidal shape. It is worth noting that 
methods for describing the kinetic behavior of qRT-LAMP have only started to emerge in 
the past year[59], and most behavioral models are adopted from the literature of qRT-PCR 
without being fitted to measured trends[60,61]. For our own purposes, we observed that 
performing LAMP directly in complex samples, such as bacterial cell lysate and crudely 
lysed blood, would affect the baseline signal and enzymatic efficiency. Non-idealities from 
either the smartphone-based detection system or from the endogenous macromolecules in 
the aforementioned lysates caused noisy fluctuations in the time-course signal. Two 
smoothing approaches were used to combat this:  first, a moving average de-noising filter; 
second, a coarse derivative technique. 
The coarse derivative mechanism is essential in transforming a real-time curve into a Tt 
value that is linearly related to the logarithm of the input concentration. The first step in 
manipulating the signal curve is the application of a smoothing filter that averages each 
point with the ten surrounding point values. Though this will help correct for small changes 
in the measured fluorescence, it will not account for variations in amplification efficiencies, 
ground-phase minima, or plateau-phase maxima. To combat such behavioral deviances 
between samples, we defined Tt as the maximum of the derivative of a coarse model of the 
real-time curve. Based off of the first derivative maximum (FDM) method[62], the coarse 
derivative technique avoids false positives that arise from errant noise in the finite first-
derivative curve and accounts for sample-dependent variations in amplification efficiencies 
or time-course minima and maxima.  
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Instead of computing the signal difference on a point-to-point scale, the coarse derivative 
takes the difference over a coarse timestepper, i.e. a chosen length of time over which to 
average. The coarse differential of a given system U with time step δt, where time tk = kδt, is  
 
Equation 3.1 Coarse derivative function used to differentiate an output signal U according to a set 
timestepper δt.  
 
In our case, the optimal δt was empirically determined to be the average rise time from the 
ground phase to the plateau phase, or 220 seconds. Using the average rise time as a 
timestepper allows us to compute the timescale derivative of our fluorescence measurements 
in a way that is more tractable than attempting a finite first derivative, yet commensurate 
with the measured trends. Tt is hence defined as the maximum signal change over a 220-
second time step. 
 
References 
[1] R. F. Khabbaz, R. R. Moseley, R. J. Steiner, A. M. Levitt, B. P. Bell, Lancet 2014, 
384, 53–63. 
[2] B. (PCR I. Butkus, Report Values Global MDx Market at $11B by 2015; Projects 
qPCR to Remain Key Driver, 2012. 
[3] R. Emmadi, J. B. Boonyaratanakornkit, R. Selvarangan, V. Shyamala, B. L. Zimmer, 
L. Williams, B. Bryant, T. Schutzbank, M. M. Schoonmaker, J. a Amos Wilson, et al., 
J. Mol. Diagn. 2011, 13, 583–604. 
[4] P. Craw, W. Balachandran, Lab Chip 2012, 12, 2469–86. 
[5] H. H. Lee, M. a Dineva, Y. L. Chua, A. V Ritchie, I. Ushiro-Lumb, C. a Wisniewski, 
J. Infect. Dis. 2010, 201 Suppl , S65–S72. 
[6] P. Yager, G. J. Domingo, J. Gerdes, Annu. Rev. Biomed. Eng. 2008, 10, 107–44. 
∂U
∂t
=
Uk+1,N − Uk,N
δt
  54 
[7] A. Akane, K. Matsubara, D. Ph, H. Nakamura, S. Takahashi, K. Kimura, R. Akane, 
1994, 362–372. 
[8] L. Rossen, P. Norskov, K. Hoimstrom, O. F. Rasmussen, Int. J. Food Microbiol. 
1992, 17, 37–45. 
[9] N. Mancini, S. Carletti, N. Ghidoli, P. Cichero, R. Burioni, M. Clementi, Clin. 
Microbiol. Rev. 2010, 23, 235–251. 
[10] C. Bettegowda, M. Sausen, Sci. Transl. … 2014, 6, DOI 
10.1126/scitranslmed.3007094.Detection. 
[11] H. J. Chung, C. M. Castro, H. Im, H. Lee, R. Weissleder, Nat. Nanotechnol. 2013, 8, 
369–75. 
[12] A. Afshari, J. Schrenzel, M. Ieven, S. Harbarth, Crit. Care 2012, 16, 222. 
[13] I. G. Wilson, Appl. Environ. Microbiol. 1997, 63, 3741–3751. 
[14] J. a Platts-Mills, J. Liu, E. R. Houpt, Mucosal Immunol. 2013, 6, 876–85. 
[15] A. Niemz, T. M. Ferguson, D. S. Boyle, Trends Biotechnol. 2011, 29, 240–50. 
[16] P. M. Dark, P. Dean, G. Warhurst, Crit. Care 2009, 13, 217. 
[17] P. Gill, A. Ghaemi, Nucleosides. Nucleotides Nucleic Acids 2008, 27, 224–43. 
[18] R. D. Stedtfeld, M. Stedtfeld, M. Kronlein, G. Seyrig, R. J. Ste, A. M. Cupples, S. A. 
Hashsham, Environ. Sci. Technol. 2014, 48, 13855–13863. 
[19] R. D. Stedtfeld, D. M. Tourlousse, G. Seyrig, T. M. Stedtfeld, M. Kronlein, S. Price, 
F. Ahmad, E. Gulari, J. M. Tiedje, S. a Hashsham, Lab Chip 2012, 12, 1454–62. 
[20] L. Jiang, M. Mancuso, Z. Lu, G. Akar, E. Cesarman, D. Erickson, Sci. Rep. 2014, 4, 
4137. 
[21] W. A. Al-soud, P. Rådström, J. Clin. Microbiol. 2000, 38. 
[22] T. Cai, G. Lou, J. Yang, D. Xu, Z. Meng, J. Clin. Virol. 2008, 41, 270–276. 
[23] E. T. Han, R. Watanabe, J. Sattabongkot, B. Khuntirat, J. Sirichaisinthop, H. Iriko, L. 
Jin, S. Takeo, T. Tsuboi, J. Clin. Microbiol. 2007, 45, 2521–2528. 
[24] P. Francois, M. Tangomo, J. Hibbs, E.-J. Bonetti, C. C. Boehme, T. Notomi, M. D. 
Perkins, J. Schrenzel, FEMS Immunol. Med. Microbiol. 2011, 62, 41–8. 
  55 
[25] N. W. Lucchi, A. Demas, J. Narayanan, D. Sumari, A. Kabanywanyi, S. P. Kachur, J. 
W. Barnwell, V. Udhayakumar, PLoS One 2010, 5, e13733. 
[26] J.-L. Yang, G.-P. Ma, R. Yang, S.-Q. Yang, L.-Z. Fu, a-C. Cheng, M.-S. Wang, S.-H. 
Zhang, K.-F. Shen, R.-Y. Jia, et al., J. Appl. Microbiol. 2010, 109, 1715–23. 
[27] D. M. Heithoff, W. R. Shimp, J. K. House, Y. Xie, B. C. Weimer, R. L. Sinsheimer, 
M. J. Mahan, PLoS Pathog. 2012, 8, DOI 10.1371/journal.ppat.1002647. 
[28] D. M. Heithoff, R. L. Sinsheimer, D. a Low, M. J. Mahan, Science 1999, 284, 967–
970. 
[29] N. a Feasey, G. Dougan, R. a Kingsley, R. S. Heyderman, M. a Gordon, Lancet 2012, 
379, 2489–99. 
[30] Y. Mori, M. Kitao, N. Tomita, T. Notomi, J. Biochem. Biophys. Methods 2004, 59, 
145–157. 
[31] A. S. Patterson, D. M. Heithoff, B. S. Ferguson, H. T. Soh, M. J. Mahan, K. W. 
Plaxco, Appl. Environ. Microbiol. 2013, 79, 2302–11. 
[32] R. a. Edwards, G. J. Olsen, S. R. Maloy, Trends Microbiol. 2002, 10, 94–99. 
[33] K. Nagamine, T. Hase, T. Notomi, Mol. Cell. Probes 2002, 16, 223–229. 
[34] T. Bar, M. Kubista, A. Tichopad, Nucleic Acids Res. 2012, 40, 1395–406. 
[35] B. J. Taylor, K. a Martin, E. Arango, O. M. Agudelo, A. Maestre, S. K. Yanow, 
Malar. J. 2011, 10, 244. 
[36] Z. Zhang, M. B. Kermekchiev, W. M. Barnes, J. Mol. diagnostics 2010, 12. 
[37] M. B. Kermekchiev, L. I. Kirilova, E. E. Vail, W. M. Barnes, Nucleic Acids Res. 
2009, 37, e40. 
[38] K. Hayashida, K. Kajino, L. Hachaambwa, B. Namangala, C. Sugimoto, PLoS Negl. 
Trop. Dis. 2015, 9, e0003578. 
[39] J. R. Port, C. Nguetse, S. Adukpo, T. P. Velavan, Malar. J. 2014, 13, 454. 
[40] J. Sirichaisinthop, S. Buates, R. Watanabe, E. T. Han, W. Suktawonjaroenpon, S. 
Krasaesub, S. Takeo, T. Tsuboi, J. Sattabongkot, Am. J. Trop. Med. Hyg. 2011, 85, 
594–596. 
  56 
[41] R. Howard, J. B. S. Leathart, D. J. French, E. Krishan, H. Kohnke, M. Wadelius, R. 
Van Schie, T. Verhoef, A. H. Maitland-van der Zee, A. K. Daly, et al., Clin. Chim. 
Acta 2011, 412, 2063–2069. 
[42] J. H. Chen, F. Lu, C. S. Lim, J. Y. Kim, H. J. Ahn, I. B. Suh, S. Takeo, T. Tsuboi, J. 
Sattabongkot, E. T. Han, Acta Trop. 2010, 113, 61–65. 
[43] D. H. Paris, S. D. Blacksell, P. N. Newton, N. P. J. Day, Trans. R. Soc. Trop. Med. 
Hyg. 2008, 102, 1239–46. 
[44] K. a Curtis, D. L. Rudolph, S. M. Owen, J. Med. Virol. 2009, 81, 966–72. 
[45] L. L. M. Poon, B. W. Y. Wong, E. H. T. Ma, K. H. Chan, L. M. C. Chow, W. 
Abeyewickreme, N. Tangpukdee, K. Y. Yuen, Y. Guan, S. Looareesuwan, et al., Clin. 
Chem. 2006, 52, 300–3. 
[46] J. Beige, J. Lokies, T. Schaberg, U. Finckh, M. Fischer, H. Mauch, J. Clin. Microbiol. 
1995, 33, 90–95. 
[47] D. J. Grab, O. V Nikolskaia, N. Inoue, O. M. M. Thekisoe, L. J. Morrison, W. 
Gibson, J. S. Dumler, PLoS Negl. Trop. Dis. 2011, 5, e1249. 
[48] M. Soejima, K. Egashira, H. Kawano, A. Kawaguchi, K. Sagawa, Y. Koda, J. Mol. 
Diagn. 2011, 13, 334–9. 
[49] E. Scallan, R. M. Hoekstra, F. J. Angulo, R. V. Tauxe, M.-A. Widdowson, S. L. Roy, 
J. L. Jones, P. M. Griffin, Emerg. Infect. Dis. 2011, 17, 7–15. 
[50] S. J. Peacock, Nature 2014, 509, 557–559. 
[51] D. G. Maki, N. Engl. J. Med. 2009, 360, 949–953. 
[52] J. R. Andrews, E. T. Ryan, Vaccine 2015, 33, C8–C15. 
[53] A. Kumar, D. Roberts, K. E. Wood, B. Light, J. E. Parrillo, S. Sharma, R. Suppes, D. 
Feinstein, S. Zanotti, L. Taiberg, et al., Crit. Care Med. 2006, 34, 1589–1596. 
[54] C. F. Fronczek, T. S. Park, D. K. Harshman, A. M. Nicolini, J.-Y. Yoon, RSC Adv. 
2014, 4, 11103. 
[55] N. J. Loman, C. Constantinidou, J. Z. M. Chan, M. Halachev, M. Sergeant, C. W. 
Penn, E. R. Robinson, M. J. Pallen, Nat. Publ. Gr. 2012, 10, 599–606. 
[56] K. H. Hecker, K. H. Roux, Biotechniques 1996, 20, 478–85. 
[57] D. J. Korbie, J. S. Mattick, Nat. Protoc. 2008, 3, 1452–6. 
  57 
[58] R. Surabattula, M. P. Vejandla, P. C. Mallepaddi, K. Faulstich, R. Polavarapu, Exp. 
Parasitol. 2013, 134, 333–340. 
[59] S. Subramanian, R. D. Gomez, PLoS One 2014, 9, 1–10. 
[60] J. Tellinghuisen, A.-N. Spiess, Anal. Biochem. 2014, 449, 76–82. 
[61] A. Tichopad, A. Didier, M. W. Pfaffl, Mol. Cell. Probes 2004, 18, 45–50. 
[62] A. Tichopad, M. Dilger, G. Schwarz, M. W. Pfaffl, Nucleic Acids Res. 2003, 31, 
122e–122.  
 
  58 
Chapter IV. Generating aptamer affinity reagents to 
unlock, isolate, and identify a portion of the Chinese 
hamster ovary cell proteome3 
Introduction 
For all the progress that biopharmaceuticals have made in creating personalized, 
efficacious therapeutics, the power of these recombinantly expressed proteins has yet to 
conquer its greatest adversary:  the host cell. Mammalian production cell lines generate 
recombinant therapeutics to the tune of $113B in annual revenue for the biologics 
industry[1]. Ironically, the cells also make a complex, heterogeneous, process-dependent 
population of host cell proteins (or HCPs, which are on the order of 1,200-1,400 for Chinese 
hamster ovary-derived HCPs[2]) that can cause a toxic immunogenic response in humans. 
While HCPs may serve important functions within the cells, these reductases, proteases, and 
glycosylases will degrade, inhibit, or otherwise hinder the functionality of the cell-produced 
therapeutics[3]. HCPs emerge in the bioreactor either through cell lysis or co-secretion with 
the product of interest, and must be measured, monitored, and controlled in order to meet 
regulatory standards by the FDA and other global health authorities. While there are many 
unique ways of measuring residual HCPs and genomic DNA, it remains an industry-wide 
challenge to find assays that can suitably and accurately detect HCPs at a level that will 
meet regulatory requirements. 
The test used for monitoring levels of HCP impurities must be sensitive, yet broadly 
based:  these proteins have diverse physicochemical properties and are present at only 1-100 
ppm (or nanogram HCPs per milligram of drug substance, ng/mg) in the final stages of 
                                                
3 At the date of compiling this thesis, September 2015, this work is still in progress. The 
contents are thus presented as preliminary results. 
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downstream processing. Most commonly, an enzyme-linked immunosorbent assay (ELISA) 
is used to provide numerical results that are amenable for setting control limits and 
specifications. This format relies on polyclonal antibodies (pAbs)—derived from specially 
immunized animals treated with a broad array of HCP species—as its HCP detection 
reagents. Though it is the gold standard in the industry, this approach faces limitations from 
its sandwich-assay format and its development process. Detection of HCPs requires two 
high-quality antibodies. The first is immobilized on a surface, where it binds to a single 
epitope on an HCP; the second recognizes a different epitope and reports a signal. Though 
this works in theory, measurements are realistically impeded by scenarios in which binding 
is sterically hindered, only one antibody is generated, or too few binding antibodies are 
available. Given how profiling HCPs depends on the performance of antibody pairs, it is 
unsurprising that high-quality preparation of anti-HCP antibodies is critical. Practically, the 
immunization process is lengthy (9-12 months), expensive, and challenging in terms of HCP 
coverage[4]. Maximizing antibody coverage also maximizes the procedural difficulty:  HCP 
immunogens are prepared to be free of the therapeutic drug, multiple species of animals 
(oftentimes rabbits, goats, sheep, or chickens) are immunized, multiple immunizations are 
applied, and antiserum from different animals are finally pooled after the course of several 
months. Even with these precautions, it is difficult to obtain full coverage because HCPs that 
do not cause an immunogenic response in the animal will not generate antibodies and the 
antibodies that are generated may have low affinity to certain HCPs or be in low abundance. 
Moreover, a human immune system may react in a more dire magnitude and nature to 
foreign HCPs than the animals used to generate the pAb reagent[5]. With such caveats 
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accompanying today’s standard operations, achieving better process capability in the 
biopharmaceutical industry will require a break from conformity and convention.  
Manufacturers of biologics recognize that one size does not fit all in HCP evaluation. 
Orthogonal approaches to traditional antibody-based techniques have been incorporated in 
analysis and control pipelines, but each specific bioprocess demands a goldilocks approach 
to finding the right combination of technologies for detecting, identifying, quantifying, and 
profiling HCPs. In a campaign to capitalize upon the advancements of bioinformatics, 
protemics, and genomics, we turn to affinity reagents well-suited for the post-genomic age:  
aptamers. Aptamers are single-stranded nucleic acids with target-binding capabilities. 
Aptamer generation has become a fast-paced, large-scale endeavor through the integration 
of genomic tools such as high-throughput sequencing (HTS) and array-based 
characterization[6]. Yet even as aptamers have been selected for “difficult” protein targets in 
biological samples[7], the severity of the level of difficulty in HCP detection is marked in the 
complexity of the Chinese hamster ovary (CHO) cell proteome. Not only are there 
thousands of constituents in the proteome, the state of each could be anywhere from native 
to denatured to anything in between[8]. Intracellular processes and extracellular 
modifications result in charge and size heterogeneity that accordingly confound structural 
interactions with external binders. Another important factor is the wide dynamic range of the 
levels of HCPs produced, as protein expression levels in eukaryotic cells can vary over six 
orders of magnitude[9]. In contrast to the use of traditional in vitro selection technology, 
wherein aptamers are selected for high affinity to one specific target, binding to HCPs 
requires a novel platform for biomarker discovery. A strategy suited to this task would probe 
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for multi-target binders that interact with vastly variable content. Selective dominance by a 
singly enriched family of motifs is no longer the end goal.  
In this work, we have leveraged the advent of big data technologies to identify DNA 
affinity reagents against components of the CHO proteome. This entails successively 
performing microfluidic selection, particle display screening, HTS, microarray binding 
assays, and affinity chromatography to create a defined reagent set (Figure 4.1). By using 
nontraditional tools, we are able to achieve maximum diversity in our candidate aptamers 
and avoid the pitfalls of pool dominance by the most prominent binding motifs[10]. This is 
clear in our quantitative visualization of the targeted HCPs by two-dimensional difference 
gel electrophoresis (2D-DIGE):  the measured coverage was 70%, a hair’s breadth from the 
pAb (a proprietary batch of CHO HCP antigens harvested by Medimmune, LLC using 
immunization methods) coverage of 72%. In the interest of characterizing HCPs in a manner 
amenable to the workflow in recombinant therapeutic protein production, we used our 
aptamer reagent set to isolate target HCPs through affinity-based chromatography and 
characterized the selected proteins via label-free liquid chromatography coupled with 
tandem mass spectrometry (LC-MS/MS). The differing physical attributes of bound HCPs—
calculated isoelectric points (pIs) between 4.4-9.7, molecular weights (MWs) between 22-
328 kD, and proposed functions ranging from proteases to protein binders to lipid binders—
lend further credence to the broad range of targets to which aptamers can bind. As aptamer 
reagents have the advantages over their sera-based counterparts of being more reproducible, 
tunable, and affordable, we believe they are more amenable to in vitro optimization for 
targeting HCP than pAbs. Our demonstration of the sensitivity and specificity of aptamers in 
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robustly and reliably detecting HCPs is a first step in moving beyond what is currently 
possible to produce biologics that are certifiably safe. 
 
 
 
Figure 4.1 Integrative approach for identifying aptamers to HCPs. Workflow is a confluence of 
technologies for genomics and proteomics. First, a DNA library undergoes directed evolution by 
microfluidic selection. Next, candidate aptamer pool is screened for target binding by particle display. 
HTS is used to obtain sequences of selected candidates. DNA microarrays are synthesized and 
subjected to binding tests with target HCPs to further refine candidate pool. Finally, 2D-DIGE and 
orthogonal methods are used to test the analytical performance of our aptamers in comparison to 
pAbs. 
 
Results and Discussion  
A. Using confluent technologies to generate candidate aptamers 
Our search for a set of effective anti-HCP aptamers used several selection-based 
screening approaches to obtain a defined reagent set of HCP-binding DNA sequences. The 
process of systematic evolution of ligands by exponential enrichment (SELEX) selects for 
target-binding sequences from a library pool with randomized regions by exerting 
evolutionary pressure that will favor those sequences with high affinity and specificity for 
the target[11,12]. Most in vitro selection platforms are low- or medium-throughput, being 
limited by the requirement to individually and serially measure the affinity and specificity of 
each candidate aptamer to a single, known target. In marked contrast, we modify the 
powerful quantitative parallel aptamer selection system (QPASS) to identify aptamers en 
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masse—while operating on over 1,000 targets simultaneously. QPASS entails minimally 
enriching a candidate pool of aptamers, sequencing the entire pool, and performing 
microarray-based binding assays. The introductory application of QPASS by Cho et al. 
focused on probing and profiling a single target, generating a large collection of sequencing 
and binding data. Our own extension of QPASS, in expectation of the vast data sets 
generated in this framework (millions of base reads in HTS and tens of thousands of 
fluorescent signals on arrays), fully utilized the system’s greatest asset of total, parallelized 
characterization by profiling an entire proteome. The initial pool of 1 nmol (equivalent to 
6x1014 molecules) was designed with a 50-mer random region and enriched through two 
rounds of microfluidic SELEX (M-SELEX) against HCPs immobilized on beads[13,14]. The 
protocol diverged from conventional selection with subsequent rounds of selection that used 
the particle display (PD) technique of fluorescence-activated cell sorting (FACS) to screen 
for binding of bead-affixed candidate sequences against free HCPs[15]. PD is capable of 
isolating high-affinity binders from >108 unique sequences. Its reliance on FACS screening, 
a high-throughput method to visualize target binding, allows individual sequences to be 
discarded or retained in real time.  
Five total rounds were completed—rounds 1 and 2 (R1 and R2, respectively) using M-
SELEX and rounds 3, 4, and 5 (similarly named R3, R4, and R5) using PD—when we 
began to examine the population of aptamer candidates. Flow cytometry was used to 
characterize the binding affinities of the rounds after enrichment via PD (Figure 4.2a). R5 
showed a dramatic increase in affinity for the target protein mixture, as evidenced by the 
fluorescence intensity from proteins captured by the aptamers (Figure 4.2b). The percentage 
of the R5 population that binds to HCPs, even at low target concentrations of 3 nM, is larger 
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than both R4 and R3 and indicative of successful discrimination against non-binders in the 
selection (Figure 4.2c).  
 
 
Figure 4.2 Workflow for aptamer enrichment and subsequent tests for target affinity. a. After two 
rounds of SELEX with conventional methodology, we performed further aptamer screening with three 
rounds of nontraditional PD. b. Flow cytometry of enriched aptamer sequences shows reference 
gates where aptamer particles reside abutting on the sort gate where binding sequences reside. The 
naïve library control shows only 1% of the population in the sort gate, but 13% of the R5 candidate 
pool is in the sort gate. c. Flow cytometry with 0-5 nM HCP against R3, R4, and R5 pools illustrate 
that the binding fraction of the population increased accordingly with the level of enrichment in the 
pool. 
 
Interactions with HCPs represent only one of the qualities that we desired in our 
aptamers—a preferential specificity for HCPs over other proteins is essential for a reagent 
set that will need to discriminate against high background levels of biomolecules when 
applied to process characterization studies. Again relying on flow cytometry, we challenged 
our R5 pool with increasing concentrations of immunoglobulin G (IgG). IgG is the most 
common antibody type, recognizing pathogenic viruses, bacteria, and fungi; it is often used 
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as a standard in internal quality control assays in conjunction with anti-human IgG 
monoclonal antibodies. If the aptamer pool’s performance could stand the test of retaining 
binding functionality of variable compounds, it would lend further credence to the selective 
nature of our affinity reagents. IgG from several drug makers (Sigma-Aldrich Co. and EMD 
Millipore) was introduced at concentrations over 1,000 times higher than HCPs in binding 
experiments (Figure 4.3a). As evidenced by the binding fraction that was retained by HCP, 
aptamers exhibited affinity for the HCP target in all tests and proved able to retain 
specificity in scenarios resembling processing characterization. Given this increase in 
binding ability, we cloned the R5 pool into Escherichia Coli (E. Coli) and picked 119 
clones; of these, 83 were unique. The sequences that were highly represented in families 
were further used to obtain specificity profiles against IgG using printed microarrays 
(representing Families I, II, and III in Figure 4.3c). Microarray testing was carried out on 
identical DNA-spotted slides—consisting of an epoxy substrate coupled to amino-modified 
oligonucleotides—with either HCP or IgG as the target of interest. Binding to HCP was 
evident from the fluorescence signal observed after scanning for the labeled target. Any 
signal from IgG was solely due to the intrinsic fluorescence of the substrate and background 
noise from the solution (Figure 4.3b). This survey with a limited number of sequences 
opened the door to a wider set of characterizations with more sophisticated analysis tools:  
HTS and high-density arrays. 
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Figure 4.3: Specificity tests against IgG with HCP aptamers from R5. a. R5 candidate pool of 
aptamers were subjected to flow cytometry, with varying amounts of IgG and 3 nM HCP. In up to 
5,000 nM IgG, the bead-bound aptamers still exhibited a fluorescent signal from binding to the HCP 
target. b. Sequences, obtained from R5 cloning and sequencing, of candidate aptamers containing 
C6 amino modifiers at the 5’ end were printed on epoxy-modified glass slides to create printed DNA 
microarrays. Array slides were blocked, incubated with biotinylated HCP or IgG, and labeled with 
streptavidin-Alexa 647 to simultaneously characterize the affinities and specificities of candidates in 
parallel. DNA sequences once more illustrate binding greater than the library to HCPs, while giving 
negative responses equivalent with the library in response to IgG. c. Secondary structure motifs from 
mfold representative of three families in the alignment of 119 sequences from R5 that were used in 
array binding tests in b. 
 
B. Quantitative binding measurements on array to determine final aptamer reagent set  
  67 
Our goal herein had been to increase the affinity and specificity of the candidate aptamer 
pool for HCP while separating out the chaff that would bind IgG nonspecifically. Obtaining 
the maximal coverage of the CHO proteome, from the low-abundance proteins to more 
concentrated ligands, was our next goal. There are several reasons for retaining the 
maximum possible diversity in the pool of potential aptamer candidates. Since we are 
targeting over 1,000 proteins in the mixture of HCPs, it would be undesirable for the pool to 
converge to only a few sequences of limited structural motifs[10]. To this end, we left behind 
the limitations of Sanger sequencing; similarly, we backtracked from our use of the most 
converged round and focused our first pool from PD. Against the convention of Sanger 
sequencing, we applied the QPASS practice of HTS on our R3 pool. The maximum possible 
diversity that we can analyze is hence as large as the hundreds of millions in a MiSeq 
sequencing platform (Illumina). This approach allows us to probe the DNA sequence space 
for a large number of interactions in parallel, and for rare interactions that would be entirely 
missed by evaluating a much smaller fraction of sequences.  
As HTS is capable of capturing these extremely low copy sequences and successfully 
identifying high-quality binders[16], we turned to parallelized characterization as a compass 
to guide us towards these elusive binding agents. According to convention, the number of 
reads for each unique oligonucleotide in a sequence pool should correspond to enrichment 
by target binding. The observed trends are, in practice, significantly affected by PCR bias 
and other artifacts such that a larger copy number does not necessarily indicate a larger 
binding affinity[17]. Of the three sequences used in the preliminary test with printed 
microarrays, the sequence from Family I had the lowest ranking by HTS (23,930 of 
218,557). However, it gave the highest signal response in binding tests with HCP, as well as 
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being specific for HCP over IgG (Figure 4.2c). These variations between HTS counts and 
binding performance are best faced head-on with analytical tools. Arrays continued to be a 
broad-spectrum filter for this work, as in QPASS, but with the caution that aptamer 
sequences may behave differently on arrays than they would in the final format used to 
detect HCPs. Much like the biopharmaceutical industry itself, we relied on orthogonal 
methods of bead-based pull-downs and affinity chromatography to battle these biases and 
limitations in selecting the defined set of aptamers to be used in the 2D-DIGE determination 
of HCP coverage. 
Parallel mass characterization of aptamers on microarrays has previously been used to 
identify potential aptamers from HTS data, and the high-throughput nature of this 
methodology is well-suited to assays with target proteins that number in the thousands[6].  
With the HTS results as a starting point, we performed HCP binding assays on in situ-
synthesized microarrays containing the top 6,000 sequences by copy number. As our 
aptamer library contained a 50-mer random region flanked by 20-mer primer-binding sites, 
we excised the core 50-mer portion of the sequence for in situ synthesis on the microarrays. 
Fluorescent intensities from bound HCPs—as noted in the Family I sequence of rank 
23,930—did not decline as a result of decreasing copy number, but consistently 
demonstrated values above a threshold minimum of 1.5 x 104 (AU) down to the lowest-
ranked sequences. For several dozen R5 sequences that displayed a binding signal above this 
set intensity threshold, we performed further investigations via bead-based (pull-downs) and 
resin-based (HPLC) affinity measurements. From the pull-downs of capturing HCPs in 
solution on bead-bound aptamers, six distinct families (Families I, II, and III being the same 
as above) of 22 sequences performed robustly enough to progress towards a reliable 
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calculation of HCP coverage (Figure 4.4a). Representative sequences from each family 
show very little internal folding, as secondary structures are limited to stem-loops with, at 
most, 7 base pairs (Figure 4.4b). A lack of prescribed self-folding may make the 
randomized region more available for intermolecular hydrogen binding with the target 
molecules. This possibility was put to the test in a gel electrophoresis approach to obtain the 
extent of HCPs bound by these aptamers.  
 
 
Figure 4.4: The top 6,000 candidate aptamer sequences identified by HTS (according to copy 
number) were synthesized as 50-mer microarrays to characterize their binding to the HCP target 
mixture. HTS was performed by GeneWiz. a. Aptamer sequences (R3 copy number shown) in b that 
performed well in microarray binding experiments and the orthogonal method of pull-down assays 
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fell into six distinct families. b. After blocking, synthesized microarrays of 50-mer variable regions 
were incubated with 100 nM biotinylated HCP, washed, and scanned. Fluorescence indicates level 
of binding affinity. Cutoff for further consideration in affinity-based assays was a signal of 15k. 
Consensus motifs from mfold for six families as shown (no internal binding is observed in regions of 
sequences that are not displayed). Microarray synthesis was performed by MYcroarray.  
 
Just as copy number is not predicted to be an accurate gauge of relative binding affinity, 
the microarray fluorescence measurements did not directly correlate to aptamers with high 
responses in pull-downs. Two of the R3 aptamer candidates from our preliminary 
microarray spotting test, representing family II (rank 289) and family III (rank 67), had 
shown strong fluorescent responses as full-length binders on the arrays but gave marginal 
signals on in situ–synthesized 50mer microarrays. In the face of this discrepancy, we further 
investigated the capacity in of each in pulling down HCPs as bead-immobilized reagents. 
Strong, distinct band patterns were observed from HCPs of various shapes and sizes by 
SDS-PAGE visualization in the case of each pull-down (Figure 5a). While it is known that 
the composition of proteins in a sample of HCPs is widely complex, not much has been 
accomplished in the interest of deconvoluting said mixture. We completed our progression 
from library evolution to individual sequences by confirming the identity of bound HCPs via 
LC-MS/MS. In a comparison with a library control, the two aptamers together bound 11 
HCPs (2 by the Family I aptamer and 9 by the Family II aptamer) that had proposed 
functions ranging from proteases to protein binders to lipid/ion/metal binders as determined 
by InterPro (http://www.ebi.ac.uk/interpro/) (Figure 4.5b). The heterogeneity of the HCPs 
was likewise evident in the isoelectric points (pIs, between 4.4-9.7) and molecular weights 
(MWs, between 22-328 kD) (Figure 4.5c). It has been previously shown that the pI of a 
protein has an effect on dissociation constant (Kd)[18]:  a protein with a higher pI will be 
more positively charged, which generally leads to tighter binding against negatively charged 
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DNA and hence a lower Kd. In contrast to expectations, we observe calculated pIs ranging 
down to a lower bound of 4.4. 
 
 
Figure 4.5 LC-MS/MS analysis of DNA-interacting HCPs identified by their form and function. a. 
Aptamer candidates R3-23930 and R3-289 were immobilized on beads, incubated with HCPs, and 
bound proteins were heat-eluted from the beads. This elution was run on a 4-12% Bis-Tris gel for 
SDS-PAGE and stained with SYPRO Ruby. b. After gel imaging, bands containing proteins were 
excised and TCA precipitated. Samples were sent to MS Bioworks, where a total of 11 proteins from 
the R3 aptamers were not observed in a negative control pull-down with the library. Functions shown 
were obtained via InterPro. c. Ratio of aptamer-binding spectral count to library-binding spectral 
count for statistically significant proteins is shown as a function of pI (right-hand axis) and MW (left-
hand axis). Only proteins with a spectral count >50 were included in the analysis. LC-MS/MS was 
performed by MS Bioworks. 
 
C. Analysis of eluate from aptamer- and antibody-based capture of HCPs 
For the application of our aptamers to a proteomic study of CHO HCPs, our platform 
culminated in 2D gel separation to determine the coverage of the aptamer binders in 
purifying HCPs from a stock sample. The final set of six aptamer families (Figure 4.6b) had 
been shown to bind HCPs when immobilized as printed or in situ-synthesized DNA 
microarrays, and had passed the criterion of pulling down HCPs in bead-based assays. In 
determining the extent of HCP coverage, aptamers must be immobilized as a stationary 
phase in affinity chromatography and actively bind and retain HCPs as they flow over the 
column bed, from which the HCPs can be quantified by 2-D differential gel electrophoresis 
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(2D-DIGE) (Figure 4.6a). The aptamers best suited for this setting of high-production 
manufacturing will not necessarily be those that have the largest number of copies present in 
HTS data or exhibit the highest binding ability on a microarray surface, making our quality 
check of binding by orthogonal methods a necessity. Total cell lysis was prepared and 
separated by 2D-DIGE to determine the full collection of HCPs expressed; likewise, HCPs 
that had been loaded onto an aptamer-conjugated sepharose resin column and eluted after 
extensive washing were subjected to 2D-DIGE. Many of the spots present on our aptamer-
bound sample were not present on a set of library sequences that served as a negative 
control, indicating the success of our selection process. Moreover, the series of spots bound 
by the aptamers is similar in magnitude (number of spots) and diversity (range with respect 
to isoelectric point and molecular weight) to an industry-standardized sheep anti-CHO HCP 
pAb. A side-by-side comparison demonstrates that the 70% coverage of the aptamer reagent 
set against HCPs (25 mg load) is nearly equivalent to that of the antibody set at 72% (Figure 
4.6c).  
 
 
Figure 4.6 Proteomic approach for HCP identification and evaluation to illustrate coverage of 
aptamers in comparison to pAbs. a. Consensus sequences of aptamer families are printed on 
microarrays to simultaneously characterize the affinities and specificities of candidates in parallel. 
These results are cross-correlated with aptamer:target binding pull-down assays. b. 22 aptamers 
represented six families of binding motifs, constituting the aptamer reagent set that was used as the 
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stationary phase of the column in affinity purification. c. Amino-modified aptamers or pAbs were 
coupled to an NHS-sepharose resin. HCP was loaded onto the resin, non-binders were washed 
away, and bound proteins were eluted under high salt conditions. Fractions were collected and TCA 
precipitated by MedImmune. 2D-DIGE was performed by MS Bioworks with the naïve library, the 22 
selected R3 sequences, and pAbs. Compared to the HCP load, aptamers attained 70% coverage; 
the pAbs 72%.   
 
Conclusion 
By integrating powerful analytical methods, we were able to select DNA aptamers that 
could in turn be used to extract and identify the recombinant proteins synthesized in CHO 
cells. Throughout the development process of biotherapeutics, there is an increasingly 
difficult challenge to quantitate impurity levels that fall to parts per million in the 
downstream portion of the development pipeline. In testing our aptamers for HCPs against 
IgG as an industrially relevant drug sample, we demonstrated functional binding to HCPs at 
levels of the order of 1 ppm. We walked a hard line between maintaining specificity for over 
1,200 highly diverse HCPs and avoiding interactions with IgG or otherwise irrelevant 
biomolecules. Fortunately, our modified QPASS workflow did manage to retain sequences 
that bound proteins showcasing a varied set of sizes, functions, and pIs:  measured 
molecular masses ran a gamut from 22-328 kDa, and calculated pIs from 4.4-9.7. Having 
identified these hits for individual HCPs, we further applied a 22-sequence aptamer reagent 
set to proteomic analysis of HCP by 2D-DIGE separation, wherein the R3 aptamers 
performed on par with a typical anti-HCP antibody reagent in terms of coverage. In this 
manner, we can potentially facilitate the predictable and affordable use of nucleic acids to 
regulate levels of HCPs in cell-produced therapeutic drugs. Our own study was limited to a 
small set of aptamer reagents hand-picked from over one million unique sequences 
identified in the R3 pool, indicating that ongoing efforts to perform pull-downs and column-
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based assays with the remaining sequences will lend further binding abilities to an expanded 
reagent set. Of important note is the observation that Illumina-determined copy number, 
MYcroarray-based fluorescence, and pull-down quality checks all indicated different 
information about the protein-binding abilities of the sequences examined. An integrative 
approach that considers each of these techniques, compares across platforms, and 
incorporates the best of what each has to offer is the ideal in high-throughput and proteome-
wide applications such as our own. This story has served as an introductory paragraph on a 
new page of novel platforms for biologics characterization, and much is yet to be written. 
For a start, future extensions of this assay include the development of defined reagent sets 
against HCPs expressed alongside other therapeutic molecules or by other organisms. 
 
Experimental Section 
A. HCP production culture 
A null CHO host cell line was grown using standard bioreactor conditions at the 50 L 
scale and harvested by continuous centrifugation. The resulting harvest was diafiltered into 
PBS, aliquoted and stored at -80 ºC until needed. 
 
B. Selection conditions for M-SELEX (R1, R2) and PD (R3, R4, R5) 
Initially, two rounds of M-SELEX with the target on magnetic beads were performed in 
order to reduce the library diversity before PD screening. Biotinylated aptamers were 
immobilized on streptavidin beads and resuspended at 10 mg/mL. For the first round of the 
microfluidic SELEX, 1 nmol of library (6 × 1014 molecules) was incubated with 10 µL of 
HCP (100 µg target) for five hours before washing. The beads were washed 3 times in 
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PBSMCT buffer (1x phosphate buffered saline, 1.5 mM MgCl2, and 1 mM CaCl2, 0.01% 
Tween 20) (Hyclone). The DNA was eluted from the protein target by heating the beads in 
50 ul of water for 10 minutes at 95°C. Following elution of the ssDNA off of the beads, the 
DNA was amplified and purified (Qiagen) yielding dsDNA free of primers. Single-strand 
generation by lambda exonuclease (New England Biolabs) digestion[19] resulted in DNA for 
the second round of traditional SELEX. 
DNA was immobilized on beads using emulsion PCR to generate monoclonal aptamer 
particles for PD screening. Aptamer pools on beads were incubated with biotinylated HCPs 
(bHCPs) for 1.5 hours. The bHCPs that were bound to aptamer particles were labeled with 
streptavidin phycoerythrin (SA-PE) for 15 minutes so that aptamer particles that were 
binding to proteins could emit fluorescence and be sorted. Using a BD FACS Aria II 
instrument, particles with significantly higher fluorescence than background levels were 
sorted into a collection tube. Particles were sorted at a rate of approximately 2000 events/s 
for a total of one or more hours. Following sorting, particles were directly amplified with a 
pilot PCR reaction to determine an optimal cycle number for amplification of all the 
particles that were collected. The dsDNA products resulting from this full scale 
amplification were purified using a Qiagen MinElute kit, then amplified via emulsion PCR 
to begin the next round of PD. 
 
C. Microarray printing 
Amino-modified DNA solutions were prepared at 50 uM concentration in Micro 
Spotting Solution Plus buffer (Arrayit) for coupling on SuperEpoxy 2.0 slides (Arrayit). A 
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Spotbot 2 (Arrayit) was used to print onto substrates with the following parameters:  
spacing-250 µm, printing time-0.75 seconds, humidity-80%. 
 
D. Printed microarray assays 
Printed slides were blocked for 1.5 hours with solution of 10 mg/mL casein, 0.1% 
Tween-20, 1 mM MgCl2, in 1x PBS. Binding was carried out with 10 nM biotinylated target 
(bHCP or bIgG), 2 mg/mL salmon sperm DNA, and PBSMCT with 0.01% Tween-20 for 3 
hours. Labeling of biotinylated target bound to slides done with 10 nM Streptavidin-Alexa 
Fluor 647 conjugate (Life Technologies, Thermo Fisher) in PBSMCT for 5 minutes. Slides 
were washed with PBSMCT (0.01% Tween-20), PBSMCT with Tween-20 decreased to 
0.0025%, PBSMC, and distilled H2O. Finally, slides were scanned with the red laser and 
standard red filter on a GenePix 4400A microarray scanner at 2.5 µm resolution. 
 
E. High-throughput sequencing 
High throughput sequencing was performed by GeneWiz on an Illumina MiSeq 
instrument generating approximately 7 million reads for the pool. Of the 7 million reads, 
approximately 1 million of the reads were unique sequences, and 10% of all the unique 
sequences were present in 10 copies or higher. 
   
F. Microarray characterization 
The sequences obtained from high throughput sequencing were put onto microarrays 
using in situ synthesis (MYcroarray). The array takes a 3 x 20k format, in which the top 
6,000 sequences of R3 were synthesized in triplicate in each of the three identical blocks. A 
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binding assay was carried out with 100 nM HCP through steps of blocking, binding, and 
washing. Slide was blocked with 0.5% acetylated BSA (AcBSA)/fetal bovine serum (FBS) 
for 4.5 hours. After blocking, slide was washed once with PBSMCT. Each block was 
incubated with HCP in a buffer of PBSMCT with 2 µL/mL AcBSA/salmon sperm DNA for 
7.5 hours. Following washing of the slide with PBSMCT buffer, the slide was labeled with 
10 nM SA-PE for 40 minutes. After a final wash series in PBSMCT, PBSMC, and distilled 
water, the entire slide was scanned with a GenePix 4400B microarray scanner using the red 
laser and at a resolution of 2.5 µM. 
 
G. Pull-downs 
For DNA-based capture of HCP on beads, MyOne C1 carboxylic acid beads were 
washed once with PBSMCT, twice with 20 mM NaOH, and three times with PBSMCT.  
Beads were then incubated in blocking buffer (1% BSA, 1% casein, and 0.1% Tween-20 in 
PBS) for one hour with end-over-end rotation. After three washes in PBSMCT, 10 µg 
beads/µg target were combined with biotinylated ssDNA and HCP in binding buffer 
(PBSMCT with 4 µg salmon sperm DNA/µg target) for two hours with end-over-end 
rotation. Captured proteins were eluted in denaturing buffer (20% glycerol, 20 mM EDTA, 
and 50 mM DTT in laemmli buffer) at 94 ºC for ten minutes. 
 
H. SDS-PAGE and 2D DIGE 
40 µL of protein samples in denaturing buffer were loaded onto 4-15% TGX pre-cast 
gels (Bio-Rad cat #456-1084). Gel electrophoresis was carried out at 125 V for 60 minutes. 
Visualization of bands was achieved after SYPRO Ruby Protein Gel Stain (Invitrogen cat 
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#S-12000) or SilverQuest Silver Staining (Invitrogen cat #LC6070) using the Gel Doc EZ 
system (Bio-Rad cat #170-8270). 
Applied Biomics (Hayward, CA) performed 2D-DIGE and subsequent spot counting. 
 
I. IP and LC-MS/MS 
For affinity-based column chromatography by MedImmune, a 1 mL column of NHS 
sepharose was coupled with 3’-amino modified 50-mer aptamers. An AKTA system (GE 
Healthcare) was used to load HCP diluted in PBSMCT+salmon sperm DNA over the 
column, wash with PBSMCT+salmon sperm DNA, elute with 5 mL PBSMCT+2 M NaCl. 
At this point, the elutions were TCA precipitated to concentrate proteins.  
IP profiling was performed by MS Bioworks to compare all proteins present in an 
immunoprecipitation sample with proteins present in a control sample. Samples were 
separated on 10% Bis-Tris Novex minigel (Invitrogen) using MES buffer system. Gels were 
stained with Coomassie Blue and each lane excised into ten equally sized segments. Gel 
pieces were processed using ProGest (DigiLab) by:  washing with ammonium bicarbonate, 
washing with acetonitrile, reducing with 10 mM DTT at 60 °C, alkylating with 
iodoacetamide at RT, digesting with trypsin (Promega) at 37 °C, quenching with formic 
acid. Supernatant used directly in nano LC/MS/MS with a NanoAcquity HPLC (Waters) 
system interfaced to a Q Eactive (ThermoFisher). Loaded was on a trapping column packed 
with Jupiter Proteo resin (Phenomenex), eluted at 350 nL/min. MS and MS/MS at 70k 
FWHM and 17.5k FWHM resolution, respectively. The 15 most abundant ions selected for 
MS/MS. Data was searched using Mascot with the following parameters:  enzyme-trypsin, 
database-Uniprot CHO. DAT files were parsed into Scaffold software for validation, 
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filtering, and to create non-redundant lists per each sample. A total of 255 CHO proteins 
were detected across both samples with two or more unique peptides:  158 proteins in R5-
31, 129 proteins in library, and 186 proteins in R5-150. 25 proteins were unique or 4x higher 
in R5-31 sample than library. 52 proteins were unique or 4x higher in R5-150 sample than 
library. Cutoff of 50 spectral counts was used for further analysis of individual HCPs. 
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Chapter V 
Summary and future directions 
To make something great, we must break apart from the pack. Seeing a connection 
through to its potential breathes new life into established machines and methods. Mobile 
phone cameras aren’t solely implemented for the purpose of selfies; HTS can’t be 
pigeonholed as a genomics technology only suited to million-base pair reads. It is necessary 
to head out of the regulated thinking in a laboratory to see that in the hustle and bustle of 
rural health clinics, workers will rely on more on small, fast, and portable analytical tools 
such as the P3 and smaRT-LAMP telemedicine platforms. The crossover of aptamer affinity 
reagents and therapeutic proteins is similarly tricky to approach from the orthodox stance of 
SELEX. Thinking in terms of convergence and stringency will only lead to an aptamer that 
is a one-trick pony, whereas the desired result in our screening system is a set of binders that 
have minimal enrichment, varied structural motifs, and broad diversity with which to 
capture thousands of crudely processed proteins. The crux of the matter is that these creative 
strategies work. With the arterial railway of these platforms in place, the next step is to 
address their limitations and propose how to lay tracks for their successors.  
 
A. Limits, implements, and comments on P3 
A big reason that so many care facilities, whether in the first or third world, go without 
molecular techniques such as PCR is the cost. P3 takes the well-developed technique of PCR 
and repurposes existing technologies to keep the fixed costs of P3 to a minimal $41.50. 
Conventional PCR has buildup expenses on the order of $20k—a 500-fold increase above 
P3. Optimization of equipment goes further than expenses to make P3 practically field-
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ready. Carrying out PC-PCR in a laptop instead of a PC would reduce reliance on power 
sources and increase portability. In true handheld fashion, replacing the UV transilluminator 
in our work with an add-on illuminator for the phone, consisting of low-cost blue LEDs and 
blockers to limit ambient light, would provide a repeatable and inexpensive means of end-
point readout. Another complicating factor is time. The cycling process of template 
denaturation and enzymatic amplification requires several hours to complete, but may be 
expedited with mutant enzymes that are capable of high processivities[1].  
Completely demonstrating the diagnostic capabilities of P3 would require thorough 
testing on a representative set of infected clinical samples. The adversities facing NAT of 
the gDNA of amastigotes within human blood cells—rather than purified gDNA in samples 
of human blood—multiply with the difficulties of lysing cells, releasing background human 
gDNA, and potentially introducing closely related species of human pathogenic 
trypanosomes. Though a background of thousands of host cells to a few copies of target 
gDNA is hardly trivial, one of the earliest examples of camera-recorded PCR showed 
amplification of a 142-bp product from 50 ng of the HIV genome even in 40,000 cell 
equivalents of human gDNA[2]. Modern advances have improved amplification abilities with 
inhibitor-resistant chemistries and specificity-boosting additives[3], making us optimistic 
about the possibility of reducing off-priming to unrelated gDNA in blood obtained from 
patients with Chagas disease. With ample genetic information available, this system can 
even move beyond the singly demonstrated application for Chagas disease. PCR has been 
applied to a vast range of infectious diseases, meaning that the P3 system could diagnose 
microbial pathogens responsible for HIV, hepatitis, and tuberculosis, to name a few. 
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B. Limits, implements, and comments on smaRT-LAMP 
The performance of computer processing has advanced according to Moore’s Law over 
the past four decades so that electronic devices continue to become smaller, cheaper, and 
faster[4,5]. In the face of these advancements, we can engineer handheld diagnostic tests such 
as smaRT-LAMP that could truly put into action by many users in various settings. Future 
work with this platform is only limited by our knowledge of target genomes. Reagents and 
primers for performing LAMP on West Nile Virus and Koi herpesvirus are readily available 
in a kit-based format (Eiken Chemical Co., Ltd.), making these two immediately available 
scenarios for future testing in low-resource settings. 
This union of rapid DNA amplification and real-time test readout is suited for work in 
the field, meaning that smaRT-LAMP could be physically improved by modifying the 
reaction setup to be entirely transportable. The blue light to illuminate the fluorescent 
indicator FDR and visualize the progress of qRT-LAMP could very well be emitted from the 
smartphone as another function of the Bacticount app; likewise, the blackout box used to 
block ambient light during the reactions could take the form of a clip-on module for the 
phone. Finally, providing heat is as simple and inexpensive as combining calcium oxide and 
water[6]. With these modifications, our prototype could be transformed into an instrument-
free methodology that is wholly operable outside of labs or clinics. 
 
C. Limits, implements, and comments on proteomic QPASS 
To quote Sumedha Jayasena’s words of fast-paced frisson on aptamers, they “rival 
antibodies in both therapeutic and diagnostic applications.” An expansion on this is that 
antibody-based detection methods face competition from aptamers as alternative affinity 
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reagents. Antibodies are the affinity reagent of choice for picking out HCPs from 
biotechnology products in ELISAs, but the use of a sandwich assay for characterization is 
hugely different than the use of resin-bound pAbs for the actual removal of impurities from 
a product. The development of pAbs suffers greatly from variations between batches, and 
the pAbs used to determine HCP levels in a drug will most likely be those that will give the 
best results for FDA approval in an ELISA or Western blot rather than the most accurate 
measurement of purity. Our defined set of aptamer reagents could work against this trend of 
making the ends justify the means. As bioinformatics is continuously pushing big data to the 
extreme, the time is right to seek out different modes and means of quantifying HCP 
coverage. We demonstrated via the QPASS platform that our aptamers bind to HCPs when 
immobilized on arrays—and the easy readout format of DNA microarrays is where future 
directions in deconvoluting the CHO proteome should focus. There are issues to overcome 
with attaining extremely sensitive limits of detection for HCP targets in highly convoluted 
background mixtures, as witnessed by our own specificity tests with IgG and HCPs, but an 
appropriate blocking or decoupling strategy could turn printed and in situ microarrays into 
the next standardized tool for industry testing of contaminants in recombinant therapeutics. 
 
D. Outlook 
Applications of genetic testing have spurred the creation of many innovative systems—
but creativity is not enough to foster results. In terms of NAT, isothermal techniques have 
been differentiated from PCR with claims of the former having more pros and fewer cons 
(i.e., increased speed to completion and reduced need for equipment). Early reports in 
characterizing the tolerance of LAMP for biological substances implied that LAMP was 
more robust and sensitive than PCR[7–9]—though contrary results now warn against broad 
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generalizations[10,11]. As we progressed through the characterization of our smaRT-LAMP 
and P3 systems, we heeded these cautionary tales:  in each case with purified, crude, and 
animal samples, we took care to record the actual, observed trends rather than what might be 
expected from the many precedents set with PCR. Prior researchers have neglected to 
differentiate reactions such as rolling circle amplification (RCA), strand displacement 
amplification (SDA), or LAMP from PCR when carrying out classical protocols developed 
for nucleic acid extraction, signal measurement, or post-amplification analysis[12]. This 
desire to broadly lump all DNA amplification technologies together is at odds with their 
fundamental differences. Practicality demands that there must be an empirical dimension to 
verifying NAT by experimental optimization.  
Today’s diagnostics engineers are facing issues beyond the technological; theirs is an 
uphill battle against societal norms. Consider our own nation, where the ineffective 
monitoring and processing of food continually results in mortalities from outbreaks of 
foodborne infection. Poultry, swine, and cattle farmers regularly incorporate growth-
producing antibiotics into animal feeds, which greatly increase antimicrobial resistance 
while weakening the animals’ own resistance. Unnecessary distribution of antimicrobial 
agents in both human and veterinary medicine has the same effect[13]. Developing more 
sensitive and rapid molecular methods to detect enteropathogens in food can only 
accomplish so much when preventative and preemptive efforts are brushed aside with a 
cavalier disregard. Here, we mobilize genetic testing with devices that are advancing 
exponentially. The next step is bringing about an equally fast-paced revolution with 
healthcare. Considering that a reinvention of internal regulation is required in one of the 
world’s most technically advanced countries, it should come as no surprise that third-world 
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nations affected by neglected tropical diseases are in dire need of some investment and 
advocacy to reformulate their health systems. Very few resources are invested in fighting the 
global threat of Chagas disease[14]. Movements to coordinate resources for controlling 
disease transmission and providing access to treatment require a strong partnership between 
endemic communities and relief sources. 
NAATs have been heralded as a full-force gale bringing the winds of change to POC 
diagnostics, but this promise has yet to bloom into fruition. Perhaps the most salient 
example is that it has taken nearly 20 years since the development of PCR for a molecular 
diagnostic test to gain approval for use outside of typical hospital and physician settings. In 
January of this past year, Alere’s i Influenza A&B test received the Clinical Laboratory 
Improvement Amendments (CLIA) waiver for broad usage by healthcare providers[15]. 
Despite the general lack of commercially available POC diagnostics that offer both 
sensitivity and accuracy, the recent achievement by Alere Inc. can serve as a guiding light 
towards a path for deployable NAT technologies. Our hope would be that DNA-based tests 
will continue to spin like a hurricane into the business of biotesting. The three applications 
presented in this thesis—transforming PCs for Chagas disease detection, profiling 
salmonellae biomarkers in animal samples with phones, and detecting impurities in 
biopharmaceuticals with aptamers—have electrified the space between different 
technologies by merging them together. DNA’s dual nature as a protein-binding entity and a 
helical unit truly do provide it with two twin energies that can fuel our generation’s 
advancement into the brave new world of healthcare. 
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